InstitutionBaylor College of Medicine
DepartmentDepartment of Medicine
AddressOne Baylor Plaza
Houston, TX 77030
vCardDownload vCard
    Other Positions
    InstitutionBaylor College of Medicine
    DepartmentBreast Center
    DivisionBreast Cancer Center

    Collapse Biography 
    Collapse awards and honors
    2008 - 2010Member, Board of Directors,American Statistical Association, American Statistical Association
    2011Fellow, American Statistical Association, American Statistical Association

    Collapse Overview 
    Collapse overview
    Dr. Hilsenbeck has a PhD in applied biostatistics, and has long-standing interests in biostatistical and informatics collaboration, especially in cancer research. She is the statistician of record on a number of investigator initiated multi-center clinical trials leads several of the biostatistics and informatics focused resources at Baylor, including: 1) Biostatistics and Informatics Shared Resource in the Duncan Cancer Center; 2) Biostatistics in the Duncan Institute for Clinical and Translational Research.

    Dr. Hilsenbeck's personal research interests focus on design and analysis of prognostic and predictive biomarkers studies. She is also committed to teaching. She serves on mentoring committees, leads the biostatistics course for TBMM graduate students (elective to satisfy biostatistics training requirement for other programs), and is regularly invited to teach in national and international workshops.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Qian J, Ma Y, Tahaney WM, Moyer CL, Lanier A, Hill J, Coleman D, Koupaei N, Hilsenbeck SG, Savage MI, Page BDG, Mazumdar A, Brown PH. The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth. Breast Cancer Res. 2024 Feb 05; 26(1):23. PMID: 38317231; PMCID: PMC10845800.
      Citations:    Fields:    Translation:HumansAnimalsCells
    2. Zhao N, Kabotyanski EB, Saltzman AB, Malovannaya A, Yuan X, Reineke LC, Lieu N, Gao Y, Pedroza DA, Calderon SJ, Smith AJ, Hamor CW, Safari K, Savage SR, Zhang B, Zhou J, Solis Soto LM, Hilsenbeck SG, Fan C, Perou CM, Rosen JM, Zhao N, Kabotyanski EB, Saltzman AB, Malovannaya A, Yuan X, Reineke LC, Lieu N, Gao Y, Pedroza DA, Calderon SJ, Smith AJ, Hamor C, Safari K, Savage S, Zhang B, Zhou J, Solis LM, Hilsenbeck SG, Fan C, Perou CM, Rosen JM. Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. J Clin Invest. 2023 Dec 15; 133(24). PMID: 37874652; PMCID: PMC10721161.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    3. Parker SL, Amboree TL, Bulsara S, Daheri M, Anderson ML, Hilsenbeck SG, Jibaja-Weiss ML, Zare M, Schmeler KM, Deshmukh AA, Chiao EY, Scheurer ME, Montealegre JR, Bulsara S, Anderson ML, Hilsenbeck SG, Zare M, Deshmukh AA. Self-Sampling for Human Papillomavirus Testing: Acceptability in a U.S. Safety Net Health System. Am J Prev Med. 2024 Mar; 66(3):540-547. PMID: 37935320.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    4. Zhao N, Kabotyanski EB, Saltzman AB, Malovannaya A, Yuan X, Reineke LC, Lieu N, Gao Y, Pedroza DA, Calderon SJ, Smith AJ, Hamor C, Safari K, Savage S, Zhang B, Zhou J, Solis LM, Hilsenbeck SG, Fan C, Perou CM, Rosen JM. Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. bioRxiv. 2023 Sep 28. PMID: 37808840; PMCID: PMC10557675.
    5. Veeraraghavan J, Gutierrez C, De Angelis C, Davis R, Wang T, Pascual T, Selenica P, Sanchez K, Nitta H, Kapadia M, Pavlick AC, Galvan P, Rexer B, Forero-Torres A, Nanda R, Storniolo AM, Krop IE, Goetz MP, Nangia JR, Wolff AC, Weigelt B, Reis-Filho JS, Hilsenbeck SG, Prat A, Osborne CK, Schiff R, Rimawi MF. A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 Aug 15; 29(16):3101-3109. PMID: 37195235.
      Citations:    Fields:    
    6. Kemnade JO, Florez M, Sabichi A, Zhang J, Jhaveri P, Chen G, Chen A, Miller-Chism C, Shaun B, Hilsenbeck SG, Hernandez DJ, Skinner HD, Sandulache VC. Phase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population. Oral Oncol. 2023 10; 145:106536. PMID: 37562095.
      Citations:    Fields:    Translation:Humans
    7. Kim BJ, Zheng ZY, Lei JT, Holt MV, Chen A, Peng J, Fandino D, Singh P, Kennedy H, Dou Y, Chica-Parrado MDR, Bikorimana E, Ye D, Wang Y, Hanker AB, Mohamed N, Hilsenbeck SG, Lim B, Asirvatham JR, Sreekumar A, Zhang B, Miles G, Anurag M, Ellis MJ, Chang EC. Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Res Commun. 2023 07; 3(7):1366-1377. PMID: 37501682; PMCID: PMC10370361.
      Citations:    Translation:Humans
    8. Stevens AM, Schafer ES, Li M, Terrell M, Rashid R, Paek H, Bernhardt MB, Weisnicht A, Smith WT, Keogh NJ, Alozie MC, Oviedo HH, Gonzalez AK, Ilangovan T, Mangubat-Medina A, Wang H, Jo E, Rabik CA, Bocchini C, Hilsenbeck S, Ball ZT, Cooper TM, Redell MS. Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated. Cancers (Basel). 2023 Feb 20; 15(4). PMID: 36831684; PMCID: PMC9954468.
    9. Lee HS, Jang HJ, Ramineni M, Wang DY, Ramos D, Choi JM, Splawn T, Espinoza M, Almarez M, Hosey L, Jo E, Hilsenbeck S, Amos CI, Ripley RT, Burt BM. A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2023 02 01; 29(3):548-559. PMID: 36469573; PMCID: PMC9898180.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    10. Echeverria GV, Cai S, Tu Y, Shao J, Powell E, Redwood AB, Jiang Y, McCoy A, Rinkenbaugh AL, Lau R, Trevarton AJ, Fu C, Gould R, Ravenberg EE, Huo L, Candelaria R, Santiago L, Adrada BE, Lane DL, Rauch GM, Yang WT, White JB, Chang JT, Moulder SL, Symmans WF, Hilsenbeck SG, Piwnica-Worms H. Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. NPJ Breast Cancer. 2023 Jan 10; 9(1):2. PMID: 36627285; PMCID: PMC9831981.
    11. Garcia-Recio S, Hinoue T, Wheeler GL, Kelly BJ, Garrido-Castro AC, Pascual T, De Cubas AA, Xia Y, Felsheim BM, McClure MB, Rajkovic A, Karaesmen E, Smith MA, Fan C, Ericsson PIG, Sanders ME, Creighton CJ, Bowen J, Leraas K, Burns RT, Coppens S, Wheless A, Rezk S, Garrett AL, Parker JS, Foy KK, Shen H, Park BH, Krop I, Anders C, Gastier-Foster J, Rimawi MF, Nanda R, Lin NU, Isaacs C, Marcom PK, Storniolo AM, Couch FJ, Chandran U, Davis M, Silverstein J, Ropelewski A, Liu MC, Hilsenbeck SG, Norton L, Richardson AL, Symmans WF, Wolff AC, Davidson NE, Carey LA, Lee AV, Balko JM, Hoadley KA, Laird PW, Mardis ER, King TA, AURORA US Network, Perou CM. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nat Cancer. 2023 01; 4(1):128-147. PMID: 36585450; PMCID: PMC9886551.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    12. Petrosyan V, Dobrolecki LE, Thistlethwaite L, Lewis AN, Sallas C, Srinivasan RR, Lei JT, Kovacevic V, Obradovic P, Ellis MJ, Osborne CK, Rimawi MF, Pavlick A, Shafaee MN, Dowst H, Jain A, Saltzman AB, Malovannaya A, Marangoni E, Welm AL, Welm BE, Li S, Wulf GM, Sonzogni O, Huang C, Vasaikar S, Hilsenbeck SG, Zhang B, Milosavljevic A, Lewis MT. Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach. iScience. 2023 Jan 20; 26(1):105799. PMID: 36619972; PMCID: PMC9813793.
      Citations: 4     
    13. Lin M, Ku AT, Dong J, Yue F, Jiang W, Ibrahim AA, Peng F, Creighton CJ, Nagi C, Gutierrez C, Rosen JM, Zhang XH, Hilsenbeck SG, Chen X, Du YN, Huang S, Shi A, Fan Z, Li Y. STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential. Oncogene. 2022 11; 41(48):5214-5222. PMID: 36261627; PMCID: PMC9701164.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    14. Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, Doan A, Colace SI, Guinipero T, Otterson D, Kaplan JA, Hinson A, Pommert L, Wayne AS, Bhojwani D, Burke MJ. Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatr Blood Cancer. 2022 10; 69(10):e29812. PMID: 35726868.
      Citations:    Fields:    
    15. Sapienza LG, Thomas JJ, Showalter TN, Echeverria AE, Ludwig MS, Chen AC, Jo E, Hilsenbeck SG, Jhingran A, Frumovitz MM, Calsavara VF, Baiocchi G. Endoscopic assessment of radiological stage IVA cervical cancer: A bivariate meta-analysis supporting an evidence-based staging algorithm proposal. Gynecol Oncol. 2022 06; 165(3):642-649. PMID: 35410732.
      Citations: 1     Fields:    Translation:Humans
    16. Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, Du L, Kim JA, Dustin D, Lo HC, Beyer AR, Edwards DG, Gonzalez T, Tsimelzon A, Huang HJ, Fernandez NM, Grimm SL, Hilsenbeck SG, Liu D, Xu J, Alaniz A, Li S, Mills GB, Janku F, Kittler R, Zhang XH, Coarfa C, Foulds CE, Symmans WF, Fuqua SAW, And? S. Correction to: Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2022 Jan; 41(3):460. PMID: 34782721.
      Citations:    Fields:    
    17. Gao Y, Kabotyanski EB, Shepherd JH, Villegas E, Acosta D, Hamor C, Sun T, Montmeyor-Garcia C, He X, Dobrolecki LE, Westbrook TF, Lewis MT, Hilsenbeck SG, Zhang XH, Perou CM, Rosen JM. Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics. Cancer Res Commun. 2021 12; 1(3):178-193. PMID: 35156101; PMCID: PMC8827906.
      Citations: 1     
    18. Hong Y, Limback D, Elsarraj HS, Harper H, Haines H, Hansford H, Ricci M, Kaufman C, Wedlock E, Xu M, Zhang J, May L, Cusick T, Inciardi M, Redick M, Gatewood J, Winblad O, Aripoli A, Huppe A, Balanoff C, Wagner JL, Amin AL, Larson KE, Ricci L, Tawfik O, Razek H, Meierotto RO, Madan R, Godwin AK, Thompson J, Hilsenbeck SG, Futreal A, Thompson A, Hwang ES, Fan F, Behbod F, Grand Challenge PRECISION Consortium. Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy. J Pathol. 2022 02; 256(2):186-201. PMID: 34714554; PMCID: PMC8738143.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    19. Young A, Bu W, Jiang W, Ku A, Kapali J, Dhamne S, Qin L, Hilsenbeck SG, Du YN, Li Y. Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer. Cancer Prev Res (Phila). 2022 01; 15(1):3-10. PMID: 34667127; PMCID: PMC8741732.
      Citations: 1     Fields:    Translation:HumansAnimals
    20. De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Guarducci C, Malorni L, Litchfield LM, Liu J, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, Rimawi MF, Jansen VM, Jeselsohn R, Osborne CK, Schiff R. Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 Sep 01; 27(17):4939. PMID: 34470810.
      Citations:    Fields:    
    21. Von Hoff DD, Clark GM, Coltman CA, Disis ML, Eckhardt SG, Ellis LM, Foti M, Garrett-Mayer E, Hidalgo M, Hilsenbeck SG, Littlefield JH, LoRusso PM, Lyerly HK, Meropol NJ, Patel JD, Piantadosi S, Post DA, Regan MM, Shyr Y, Tempero MA, Tepper JE, Von Roenn J, Weiner LM, Young DC, Vu NV, G?nen M. A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. Clin Cancer Res. 2021 10 15; 27(20):5472-5481. PMID: 34312215; PMCID: PMC8530870.
      Citations: 1     Fields:    Translation:Humans
    22. Yue F, Jiang W, Ku AT, Young AIJ, Zhang W, Souto EP, Gao Y, Yu Z, Wang Y, Creighton CJ, Nagi C, Wang T, Hilsenbeck SG, Feng XH, Huang S, Coarfa C, Zhang XH, Liu Q, Lin X, Li Y. A Wnt-Independent LGR4-EGFR Signaling Axis in Cancer Metastasis. Cancer Res. 2021 09 01; 81(17):4441-4454. PMID: 34099494; PMCID: PMC8416783.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    23. Veeraraghavan J, Gutierrez C, Sethunath V, Mehravaran S, Giuliano M, Shea MJ, Mitchell T, Wang T, Nanda S, Pereira R, Davis R, Goutsouliak K, Qin L, De Angelis C, Diala I, Lalani AS, Nagi C, Hilsenbeck SG, Rimawi MF, Osborne CK, Schiff R. Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. NPJ Breast Cancer. 2021 May 27; 7(1):63. PMID: 34045483; PMCID: PMC8159999.
      Citations: 1     
    24. Wang X, Veeraraghavan J, Liu CC, Cao X, Qin L, Kim JA, Tan Y, Loo SK, Hu Y, Lin L, Lee S, Shea MJ, Mitchell T, Li S, Ellis MJ, Hilsenbeck SG, Schiff R, Wang XS. Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. Clin Cancer Res. 2021 05 01; 27(9):2648-2662. PMID: 33542078; PMCID: PMC8653766.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    25. De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Guarducci C, Malorni L, Litchfield LM, Liu J, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, Rimawi MF, Jansen VM, Jeselsohn R, Osborne CK, Schiff R. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 09 01; 27(17):4870-4882. PMID: 33536276; PMCID: PMC8628647.
      Citations: 11     Fields:    Translation:HumansCells
    26. Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, Du L, Kim JA, Dustin D, Lo HC, Beyer AR, Edwards DG, Gonzalez T, Tsimelzon A, Huang HJ, Fernandez NM, Grimm SL, Hilsenbeck SG, Liu D, Xu J, Alaniz A, Li S, Mills GB, Janku F, Kittler R, Zhang XH, Coarfa C, Foulds CE, Symmans WF, Fuqua SAW, And? S. Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011. PMID: 33323970; PMCID: PMC8020875.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    27. Montealegre JR, Anderson ML, Hilsenbeck SG, Chiao EY, Cantor SB, Parker SL, Daheri M, Bulsara S, Escobar B, Deshmukh AA, Jibaja-Weiss ML, Zare M, Scheurer ME. Mailed self-sample HPV testing kits to improve cervical cancer screening in a safety net health system: protocol for a hybrid effectiveness-implementation randomized controlled trial. Trials. 2020 Oct 21; 21(1):872. PMID: 33087164; PMCID: PMC7580009.
      Citations: 1     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    28. Horne VE, Bielamowicz K, Nguyen J, Hilsenbeck S, Lindsay H, Sonabend R, Wood AC, Okcu F, Sisley S. Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. Pediatr Blood Cancer. 2020 07; 67(7):e28379. PMID: 32383818.
      Citations: 2     Fields:    Translation:Humans
    29. Elsarraj HS, Hong Y, Limback D, Zhao R, Berger J, Bishop SC, Sabbagh A, Oppenheimer L, Harper HE, Tsimelzon A, Huang S, Hilsenbeck SG, Edwards DP, Fontes J, Fan F, Madan R, Fangman B, Ellis A, Tawfik O, Persons DL, Fields T, Godwin AK, Hagan CR, Swenson-Fields K, Coarfa C, Thompson J, Behbod F. BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression. NPJ Breast Cancer. 2020; 6:12. PMID: 32352029; PMCID: PMC7181646.
      Citations: 5     
    30. Zheng ZY, Anurag M, Lei JT, Cao J, Singh P, Peng J, Kennedy H, Nguyen NC, Chen Y, Lavere P, Li J, Du XH, Cakar B, Song W, Kim BJ, Shi J, Seker S, Chan DW, Zhao GQ, Chen X, Banks KC, Lanman RB, Shafaee MN, Zhang XH, Vasaikar S, Zhang B, Hilsenbeck SG, Li W, Foulds CE, Ellis MJ, Chang EC. Neurofibromin Is an Estrogen Receptor-a Transcriptional Co-repressor in Breast Cancer. Cancer Cell. 2020 03 16; 37(3):387-402.e7. PMID: 32142667; PMCID: PMC7286719.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    31. Lau-Min K, Prakash P, Jo E, Thrift AP, Hilsenbeck S, Musher BL. Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System. Clin Colorectal Cancer. 2020 06; 19(2):e49-e57. PMID: 32165040; PMCID: PMC7261246.
      Citations: 2     Fields:    Translation:Humans
    32. De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Rexer B, Forero A, Wolff AC, Veeraraghavan J, Krop I, Pavlick AC, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF, Prat A, Pascual T, Cort?s J, Par? L, Morales S, Adamo B, Bras?-Maristany F, Vidal M, Galv?n P, Bermejo B. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. J Natl Cancer Inst. 2020 01 01; 112(1):46-54. PMID: 31037288; PMCID: PMC7850037.
      Citations: 38     Fields:    Translation:Humans
    33. Ochsner SA, Abraham D, Martin K, Ding W, McOwiti A, Kankanamge W, Wang Z, Andreano K, Hamilton RA, Chen Y, Hamilton A, Gantner ML, Dehart M, Qu S, Hilsenbeck SG, Becnel LB, Bridges D, Ma'ayan A, Huss JM, Stossi F, Foulds CE, Kralli A, McDonnell DP, McKenna NJ. The Signaling Pathways Project, an integrated 'omics knowledgebase for mammalian cellular signaling pathways. Sci Data. 2019 10 31; 6(1):252. PMID: 31672983; PMCID: PMC6823428.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    34. Rimawi MF, Niravath P, Wang T, Rexer BN, Forero A, Wolff AC, Nanda R, Storniolo AM, Krop I, Goetz MP, Nangia JR, Jiralerspong S, Pavlick A, Veeraraghavan J, De Angelis C, Gutierrez C, Schiff R, Hilsenbeck SG, Osborne CK, Translational Breast Cancer Research Consortium. TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 02 15; 26(4):821-827. PMID: 31662331.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    35. De Angelis C, Nagi C, Hoyt CC, Liu L, Roman K, Wang C, Zheng Y, Veeraraghavan J, Sethunath V, Nuciforo P, Wang T, Tsimelzon A, Mao S, Hilsenbeck SG, Trivedi MV, Cataldo ML, Pavlick A, Wolff AC, Weigelt B, Reis-Filho JS, Prat A, Gutierrez C, Osborne CK, Rimawi MF, Schiff R. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clin Cancer Res. 2020 02 01; 26(3):738-745. PMID: 31653641; PMCID: PMC7002194.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    36. Yuan Y, Lee JJ, Hilsenbeck SG. Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority. JCO Precis Oncol. 2019; 3. PMID: 32923856; PMCID: PMC7446379.
      Citations: 7     Fields:    
    37. Sethunath V, Hu H, De Angelis C, Veeraraghavan J, Qin L, Wang N, Wang T, Fu X, Nardone A, Pereira R, Nanda S, Griffith OL, Tsimelzon A, Shaw C, Chamness GC, Reis-Filho JS, Weigelt B, Heiser LM, Hilsenbeck SG, Huang S, Rimawi MF, Gray JW, Osborne CK, Schiff R, Simon LM. Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. Mol Cancer Res. 2019 11; 17(11):2318-2330. PMID: 31420371; PMCID: PMC6825570.
      Citations: 19     Fields:    Translation:HumansCells
    38. Lupo PJ, Schraw JM, Desrosiers TA, Nembhard WN, Langlois PH, Canfield MA, Copeland G, Meyer RE, Brown AL, Chambers TM, Sok P, Danysh HE, Carozza SE, Sisoudiya SD, Hilsenbeck SG, Janitz AE, Oster ME, Scheuerle AE, Schiffman JD, Luo C, Mian A, Mueller BA, Huff CD, Rasmussen SA, Scheurer ME, Plon SE. Association Between Birth Defects and Cancer Risk Among Children and Adolescents in a Population-Based Assessment of 10 Million Live Births. JAMA Oncol. 2019 Aug 01; 5(8):1150-1158. PMID: 31219523; PMCID: PMC6587148.
      Citations: 30     Fields:    
    39. Niravath P, Hilsenbeck SG, Wang T, Jiralerspong S, Nangia J, Pavlick A, Ademuyiwa F, Frith A, Ma C, Park H, Rigden C, Suresh R, Ellis M, Kent Osborne C, Rimawi MF. Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. Breast Cancer Res Treat. 2019 Sep; 177(2):427-435. PMID: 31218477.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    40. Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, Contreras A, Nuciforo P, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Wolff AC, Krop IE, Fuqua SAW, Prat A, Hilsenbeck SG, Weigelt B, Reis-Filho JS, Gutierrez C, Osborne CK, Rimawi MF, Schiff R. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. Ann Oncol. 2019 06 01; 30(6):927-933. PMID: 30903140; PMCID: PMC6594453.
      Citations: 17     Fields:    Translation:Humans
    41. Xia J, Chiu LY, Nehring RB, Mei Q, Perez M, Zhai Y, Fitzgerald DM, Pribis JP, Wang Y, Hu CW, Powell RT, LaBonte SA, Jalali A, Lentzsch AM, Szafran AT, Joshi MC, Richters M, Gibson JL, Frisch RL, Hastings PJ, Bates D, Queitsch C, Hilsenbeck SG, Coarfa C, Hu JC, Siegele DA, Scott KL, Liang H, Mancini MA, Herman C, Miller KM, Rosenberg SM, Bravo N??ez MA, Matadamas Guzm?n ML. Bacteria-to-Human Protein Networks Reveal Origins of Endogenous DNA Damage. Cell. 2019 01 10; 176(1-2):127-143.e24. PMID: 30633903; PMCID: PMC6344048.
      Citations: 35     Fields:    Translation:HumansCells
    42. Nardone A, Weir H, Delpuech O, Brown H, De Angelis C, Cataldo ML, Fu X, Shea MJ, Mitchell T, Veeraraghavan J, Nagi C, Pilling M, Rimawi MF, Trivedi M, Hilsenbeck SG, Chamness GC, Jeselsohn R, Osborne CK, Schiff R. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339. PMID: 30555156; PMCID: PMC6353941.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    43. Bielamowicz K, Okcu MF, Sonabend R, Paulino AC, Hilsenbeck SG, Dreyer Z, Suzawa H, Bryant R, Adesina A, Dauser R, Mahajan A, Chintagumpala M. Hypothyroidism after craniospinal irradiation with proton or photon therapy in patients with medulloblastoma. Pediatr Hematol Oncol. 2018 May; 35(4):257-267. PMID: 30537887.
      Citations: 4     Fields:    Translation:Humans
    44. Foster JH, Thompson PA, Bernhardt MB, Margolin JF, Hilsenbeck SG, Jo E, Marquez-Do DA, Scheurer ME, Schafer ES. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities. Cancer Chemother Pharmacol. 2019 02; 83(2):349-360. PMID: 30488179.
      Citations: 1     Fields:    Translation:Humans
    45. Neelakantan D, Zhou H, Oliphant MUJ, Zhang X, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, Lewis MT, Ford HL, Simon LM. Publisher Correction: EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun. 2018 11 12; 9(1):4720. PMID: 30420638; PMCID: PMC6232083.
      Citations: 3     Fields:    
    46. Scollon S, Majumder MA, Bergstrom K, Wang T, McGuire AL, Robinson JO, Gutierrez AM, Lee CH, Hilsenbeck SG, Plon SE, Parsons DW, Street RL. Exome sequencing disclosures in pediatric cancer care: Patterns of communication among oncologists, genetic counselors, and parents. Patient Educ Couns. 2019 04; 102(4):680-686. PMID: 30482469; PMCID: PMC6440863.
      Citations: 6     Fields:    Translation:Humans
    47. Bu W, Liu Z, Jiang W, Nagi C, Huang S, Edwards DP, Jo E, Mo Q, Creighton CJ, Hilsenbeck SG, Leavitt AD, Lewis MT, Wong STC, Li Y. Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes. Cancer Res. 2019 01 01; 79(1):61-71. PMID: 30401712; PMCID: PMC6318055.
      Citations: 14     Fields:    Translation:AnimalsCells
    48. Johnston AN, Bu W, Hein S, Garcia S, Camacho L, Xue L, Qin L, Nagi C, Hilsenbeck SG, Kapali J, Nangia J, Li Y, Podsypanina K. Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res. 2018 05 19; 20(1):42. PMID: 29778097; PMCID: PMC5960176.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    49. Chiang ACA, Fowler SW, Savjani RR, Hilsenbeck SG, Wallace CE, Cirrito JR, Das P, Jankowsky JL. Combination anti-A? treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice. J Exp Med. 2018 05 07; 215(5):1349-1364. PMID: 29626114; PMCID: PMC5940263.
      Citations: 6     Fields:    Translation:AnimalsCells
    50. Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R, Kurley SJ, Orellana M, Renwick A, Henke DM, Katsonis P, Schmitt E, Chan DW, Li H, Mao S, Petrovic I, Creighton CJ, Gutierrez C, Dubrulle J, Stossi F, Tyner JW, Lichtarge O, Lin CY, Zhang B, Scott KL, Hilsenbeck SG, Sun J, Yu X, Osborne CK, Schiff R, Christensen JG, Shields DJ, Rimawi MF, Ellis MJ, Shaw CA, Lewis MT, Westbrook TF. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med. 2018 05; 24(4):505-511. PMID: 29578538; PMCID: PMC6675908.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    51. Mo Q, Shen R, Guo C, Vannucci M, Chan KS, Hilsenbeck SG. A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. Biostatistics. 2018 01 01; 19(1):71-86. PMID: 28541380; PMCID: PMC6455926.
      Citations: 47     Fields:    Translation:Humans
    52. Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff R. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):731-740. PMID: 29110152; PMCID: PMC5821069.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    53. Niravath P, Chen B, Chapman JW, Agarwal SK, Welschhans RL, Bongartz T, Kalari KR, Shepherd LE, Bartlett J, Pritchard K, Gelmon K, Hilsenbeck SG, Rimawi MF, Osborne CK, Goss PE, Ingle JN. Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. Clin Breast Cancer. 2018 02; 18(1):78-87. PMID: 29128193; PMCID: PMC7469602.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    54. San Martin R, Pathak R, Jain A, Jung SY, Hilsenbeck SG, Sikora AG, Pienta KJ, Rowley DR, Pi?a-Barba MC. Tenascin-C and Integrin a9 Mediate Interactions of Prostate Cancer with the Bone Microenvironment. Cancer Res. 2017 11 01; 77(21):5977-5988. PMID: 28916657; PMCID: PMC8091928.
      Citations: 22     Fields:    Translation:AnimalsCells
    55. Hertz DL, Kidwell KM, Hilsenbeck SG, Oesterreich S, Osborne CK, Philips S, Chenault C, Hartmaier RJ, Skaar TC, Sikora MJ, Rae JM. CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat. 2017 Nov; 166(1):277-287. PMID: 28730340; PMCID: PMC6028015.
      Citations: 12     Fields:    Translation:Humans
    56. Neelakantan D, Zhou H, Oliphant MUJ, Zhang X, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, Lewis MT, Ford HL, Simon LM. EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun. 2017 06 12; 8:15773. PMID: 28604738; PMCID: PMC5472791.
      Citations: 71     Fields:    Translation:HumansAnimalsCells
    57. Elsarraj HS, Valdez KE, Hong Y, Grimm SL, Ricci LR, Fan F, Tawfik O, May L, Cusick T, Inciardi M, Redick M, Gatewood J, Winblad O, Hilsenbeck S, Edwards DP, Hagan CR, Godwin AK, Fabian C, Behbod F. NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer. Cancer Res. 2017 07 15; 77(14):3802-3813. PMID: 28515148; PMCID: PMC8236416.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    58. Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness GC, Park BH, Shaw CA, Hilsenbeck SG, Rimawi MF, Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, Schiff R. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5123-5134. PMID: 28487443; PMCID: PMC5762201.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    59. Guven A, Villares GJ, Hilsenbeck SG, Lewis A, Landua JD, Dobrolecki LE, Wilson LJ, Lewis MT. Carbon nanotube capsules enhance the in vivo efficacy of cisplatin. Acta Biomater. 2017 08; 58:466-478. PMID: 28465075; PMCID: PMC6344128.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    60. Gastelum GM, Iqbal C, Hilsenbeck SG, Rimawi MF, Niravath P. Retrospective review of genomic testing in breast cancer: Does it improve outcome? Breast Cancer Res Treat. 2017 May; 163(1):191-195. PMID: 28224382.
      Citations:    Fields:    Translation:Humans
    61. Nangia J, Wang T, Osborne C, Niravath P, Otte K, Papish S, Holmes F, Abraham J, Lacouture M, Courtright J, Paxman R, Rude M, Hilsenbeck S, Osborne CK, Rimawi M. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. JAMA. 2017 02 14; 317(6):596-605. PMID: 28196254.
      Citations: 45     Fields:    Translation:HumansPHPublic Health
    62. Chaudhury A, Cheema S, Fachini JM, Kongchan N, Lu G, Simon LM, Wang T, Mao S, Rosen DG, Ittmann MM, Hilsenbeck SG, Shaw CA, Neilson JR. CELF1 is a central node in post-transcriptional regulatory programmes underlying EMT. Nat Commun. 2016 11 21; 7:13362. PMID: 27869122; PMCID: PMC5121338.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    63. Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM, Anur P, Wang N, Grasso CS, Spellman PT, Griffith OL, Tsimelzon A, Gutierrez C, Huang S, Edwards DP, Trivedi MV, Rimawi MF, Lopez-Terrada D, Hilsenbeck SG, Gray JW, Brown M, Osborne CK, Schiff R. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6600-E6609. PMID: 27791031; PMCID: PMC5087040.
      Citations: 61     Fields:    Translation:HumansCells
    64. Marusyk A, Tabassum DP, Janiszewska M, Place AE, Trinh A, Rozhok AI, Pyne S, Guerriero JL, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, Rimawi MF, Hilsenbeck S, Schiff R, Osborne KC, Letai A, Polyak K. Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Res. 2016 11 15; 76(22):6495-6506. PMID: 27671678; PMCID: PMC5344673.
      Citations: 47     Fields:    Translation:HumansCells
    65. Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clin Cancer Res. 2016 Sep 01; 22(17):4291-301. PMID: 27407096; PMCID: PMC5047439.
      Citations: 37     Fields:    Translation:Humans
    66. Mazumdar A, Poage GM, Shepherd J, Tsimelzon A, Hartman ZC, Den Hollander P, Hill J, Zhang Y, Chang J, Hilsenbeck SG, Fuqua S, Kent Osborne C, Mills GB, Brown PH. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat. 2016 08; 158(3):441-54. PMID: 27393618; PMCID: PMC4963453.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    67. Parsons DW, Roy A, Yang Y, Wang T, Scollon S, Bergstrom K, Kerstein RA, Gutierrez S, Petersen AK, Bavle A, Lin FY, Monzon FA, Hicks MJ, Eldin KW, Quintanilla NM, Adesina AM, Mohila CA, Whitehead W, Jea A, Vasudevan SA, Nuchtern JG, Ramamurthy U, McGuire AL, Hilsenbeck SG, Reid JG, Muzny DM, Wheeler DA, Berg SL, Chintagumpala MM, Eng CM, Gibbs RA, Plon SE, L?pez-Terrada DH. Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. JAMA Oncol. 2016 May 01; 2(5):616-624. PMID: 26822237; PMCID: PMC5471125.
      Citations: 169     Fields:    
    68. Raj SD, Sedgwick EL, Severs FJ, Hilsenbeck SG, Wang T, Sepulveda KA. Stereotactic Biopsy of Segmental Breast Calcifications: Is Sampling of Anterior and Posterior Components Necessary? Acad Radiol. 2016 06; 23(6):682-6. PMID: 27052522.
      Citations: 1     Fields:    Translation:Humans
    69. Marcelo KL, Ribar T, Means CR, Tsimelzon A, Stevens RD, Ilkayeva O, Bain JR, Hilsenbeck SG, Newgard CB, Means AR, York B. Research Resource: Roles for Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CaMKK2) in Systems Metabolism. Mol Endocrinol. 2016 May; 30(5):557-72. PMID: 27003444; PMCID: PMC4853564.
      Citations: 17     Fields:    Translation:AnimalsCells
    70. Shepherd JH, Uray IP, Mazumdar A, Tsimelzon A, Savage M, Hilsenbeck SG, Brown PH. The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. Oncotarget. 2016 Mar 15; 7(11):13106-21. PMID: 26894864; PMCID: PMC4914345.
      Citations: 35     Fields:    Translation:HumansCells
    71. Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, Fu X, Hilsenbeck SG, Healy N, De Angelis C, Mazumdar A, Trivedi MV, Massarweh S, Gutierrez C, De Placido S, Jeselsohn R, Brown M, Brown PH, Osborne CK, Schiff R. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81. PMID: 26965145; PMCID: PMC4867274.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    72. den Hollander P, Rawls K, Tsimelzon A, Shepherd J, Mazumdar A, Hill J, Fuqua SA, Chang JC, Osborne CK, Hilsenbeck SG, Mills GB, Brown PH. Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. Cancer Res. 2016 04 01; 76(7):1942-53. PMID: 26921331; PMCID: PMC4873402.
      Citations: 39     Fields:    Translation:HumansCells
    73. Nikolai BC, Lanz RB, York B, Dasgupta S, Mitsiades N, Creighton CJ, Tsimelzon A, Hilsenbeck SG, Lonard DM, Smith CL, O'Malley BW. HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes. Cancer Res. 2016 Mar 15; 76(6):1463-75. PMID: 26833126; PMCID: PMC4794399.
      Citations: 17     Fields:    Translation:HumansCells
    74. Holdman XB, Welte T, Rajapakshe K, Pond A, Coarfa C, Mo Q, Huang S, Hilsenbeck SG, Edwards DP, Zhang X, Rosen JM. Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer. Breast Cancer Res. 2015 Nov 18; 17:141. PMID: 26581390; PMCID: PMC4652386.
      Citations: 35     Fields:    Translation:AnimalsCells
    75. Villanueva H, Visbal AP, Obeid NF, Ta AQ, Faruki AA, Wu MF, Hilsenbeck SG, Shaw CA, Yu P, Plummer NW, Birnbaumer L, Lewis MT. An essential role for Ga(i2) in Smoothened-stimulated epithelial cell proliferation in the mammary gland. Sci Signal. 2015 Sep 15; 8(394):ra92. PMID: 26373672.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    76. Kim ES, Bernstein D, Hilsenbeck SG, Chung CH, Dicker AP, Ersek JL, Stein S, Khuri FR, Burgess E, Hunt K, Ivy P, Bruinooge SS, Meropol N, Schilsky RL. Modernizing Eligibility Criteria for Molecularly Driven Trials. J Clin Oncol. 2015 Sep 01; 33(25):2815-20. PMID: 26195710.
      Citations: 34     Fields:    Translation:Humans
    77. Zheng ZY, Tian L, Bu W, Fan C, Gao X, Wang H, Liao YH, Li Y, Lewis MT, Edwards D, Zwaka TP, Hilsenbeck SG, Medina D, Perou CM, Creighton CJ, Zhang XH, Chang EC. Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. Cell Rep. 2015 Jul 21; 12(3):511-24. PMID: 26166574; PMCID: PMC4512851.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    78. Shi A, Dong J, Hilsenbeck S, Bi L, Zhang H, Li Y. The Status of STAT3 and STAT5 in Human Breast Atypical Ductal Hyperplasia. PLoS One. 2015; 10(7):e0132214. PMID: 26146825; PMCID: PMC4492667.
      Citations: 4     Fields:    Translation:Humans
    79. Ayala G, Frolov A, Chatterjee D, He D, Hilsenbeck S, Ittmann M. Expression of ERG protein in prostate cancer: variability and biological correlates. Endocr Relat Cancer. 2015 Jun; 22(3):277-87. PMID: 25972242; PMCID: PMC4432248.
      Citations: 11     Fields:    Translation:Humans
    80. Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, Mao S, Contreras A, Gutierrez C, Wang T, Hilsenbeck SG, De Angelis C, Wang NJ, Heiser LM, Gray JW, Pavlick AC, Trivedi MV, Chamness GC, Chang JC, Osborne CK, Rimawi MF, Schiff R, Lopez-Tarruella S. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015 Sep 01; 21(17):3995-4003. PMID: 26015514; PMCID: PMC4558260.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    81. Buras ED, Yang L, Saha P, Kim J, Mehta P, Yang Y, Hilsenbeck S, Kojima H, Chen W, Smith CW, Chan L. Proinsulin-producing, hyperglycemia-induced adipose tissue macrophages underlie insulin resistance in high fat-fed diabetic mice. FASEB J. 2015 Aug; 29(8):3537-48. PMID: 25953849; PMCID: PMC4511209.
      Citations: 6     Fields:    Translation:AnimalsCells
    82. Allen-Rhoades W, Kurenbekova L, Satterfield L, Parikh N, Fuja D, Shuck RL, Rainusso N, Trucco M, Barkauskas DA, Jo E, Ahern C, Hilsenbeck S, Donehower LA, Yustein JT. Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Med. 2015 Jul; 4(7):977-88. PMID: 25784290; PMCID: PMC4529336.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    83. Suo J, Medina D, Herrera S, Zheng ZY, Jin L, Chamness GC, Contreras A, Gutierrez C, Hilsenbeck S, Umar A, Foekens JA, Hanash S, Schiff R, Zhang XH, Chang EC. Int6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cells. Cell Biosci. 2015; 5:10. PMID: 25774287; PMCID: PMC4359526.
      Citations: 5     
    84. Zhang M, Tsimelzon A, Chang CH, Fan C, Wolff A, Perou CM, Hilsenbeck SG, Rosen JM. Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discov. 2015 May; 5(5):520-33. PMID: 25735774; PMCID: PMC4420701.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    85. Holloway KR, Sinha VC, Toneff MJ, Bu W, Hilsenbeck SG, Li Y. Krt6a-positive mammary epithelial progenitors are not at increased vulnerability to tumorigenesis initiated by ErbB2. PLoS One. 2015; 10(1):e0117239. PMID: 25635772; PMCID: PMC4311910.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    86. Giuliano M, Herrera S, Christiny P, Shaw C, Creighton CJ, Mitchell T, Bhat R, Zhang X, Mao S, Dobrolecki LE, Al-rawi A, Chen F, Veneziani BM, Zhang XH, Hilsenbeck SG, Contreras A, Gutierrez C, Jeselsohn RM, Rimawi MF, Osborne CK, Lewis MT, Schiff R, Trivedi MV. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3. PMID: 25572662; PMCID: PMC4318479.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    87. He B, Lanz RB, Fiskus W, Geng C, Yi P, Hartig SM, Rajapakshe K, Shou J, Wei L, Shah SS, Foley C, Chew SA, Eedunuri VK, Bedoya DJ, Feng Q, Minami T, Mitsiades CS, Frolov A, Weigel NL, Hilsenbeck SG, Rosen DG, Palzkill T, Ittmann MM, Song Y, Coarfa C, O'Malley BW, Mitsiades N. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):18261-6. PMID: 25489091; PMCID: PMC4280633.
      Citations: 55     Fields:    Translation:HumansCells
    88. Niravath P, Tham YL, Wang T, Rodriguez A, Foreman C, Hilsenbeck SG, Elledge R, Rimawi M. A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer. Oncologist. 2015 Jan; 20(1):13. PMID: 25378456; PMCID: PMC4294610.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    89. Karlin KL, Mondal G, Hartman JK, Tyagi S, Kurley SJ, Bland CS, Hsu TY, Renwick A, Fang JE, Migliaccio I, Callaway C, Nair A, Dominguez-Vidana R, Nguyen DX, Osborne CK, Schiff R, Yu-Lee LY, Jung SY, Edwards DP, Hilsenbeck SG, Rosen JM, Zhang XH, Shaw CA, Couch FJ, Westbrook TF. The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. Cell Rep. 2014 Nov 20; 9(4):1318-32. PMID: 25453754; PMCID: PMC4427000.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    90. Wei W, Tweardy DJ, Zhang M, Zhang X, Landua J, Petrovic I, Bu W, Roarty K, Hilsenbeck SG, Rosen JM, Lewis MT. STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer. Stem Cells. 2014 Oct; 32(10):2571-82. PMID: 24891218.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    91. Scollon S, Bergstrom K, Kerstein RA, Wang T, Hilsenbeck SG, Ramamurthy U, Gibbs RA, Eng CM, Chintagumpala MM, Berg SL, McCullough LB, McGuire AL, Plon SE, Parsons DW. Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients. Genome Med. 2014; 6(9):69. PMID: 25317207; PMCID: PMC4195891.
      Citations: 36     Fields:    
    92. Arteaga CL, Adamson PC, Engelman JA, Foti M, Gaynor RB, Hilsenbeck SG, Limburg PJ, Lowe SW, Mardis ER, Ramsey S, Rebbeck TR, Richardson AL, Rubin EH, Weiner GJ. AACR Cancer Progress Report 2014. Clin Cancer Res. 2014 Oct 01; 20(19 Suppl):S1-S112. PMID: 25228531; PMCID: PMC4666597.
      Citations: 19     Fields:    Translation:Humans
    93. Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430. PMID: 25212826; PMCID: PMC4303114.
      Citations: 40     Fields:    Translation:HumansAnimalsCells
    94. Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK, Hilsenbeck SG, Chang JC, Mills GB, Lau CC, Brown PH. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015 Apr 01; 21(7):1688-98. PMID: 25208879; PMCID: PMC4362882.
      Citations: 448     Fields:    Translation:HumansCells
    95. Veeraraghavan J, Tan Y, Cao XX, Kim JA, Wang X, Chamness GC, Maiti SN, Cooper LJ, Edwards DP, Contreras A, Hilsenbeck SG, Chang EC, Schiff R, Wang XS. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun. 2014 Aug 07; 5:4577. PMID: 25099679; PMCID: PMC4130357.
      Citations: 70     Fields:    Translation:HumansAnimalsCells
    96. Feng Q, Zhang Z, Shea MJ, Creighton CJ, Coarfa C, Hilsenbeck SG, Lanz R, He B, Wang L, Fu X, Nardone A, Song Y, Bradner J, Mitsiades N, Mitsiades CS, Osborne CK, Schiff R, O'Malley BW. An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul; 24(7):809-19. PMID: 24874954; PMCID: PMC4085766.
      Citations: 96     Fields:    Translation:HumansAnimalsCells
    97. Burstein MD, Robinson JO, Hilsenbeck SG, McGuire AL, Lau CC. Pediatric data sharing in genomic research: attitudes and preferences of parents. Pediatrics. 2014 Apr; 133(4):690-7. PMID: 24616359; PMCID: PMC3966500.
      Citations: 19     Fields:    Translation:Humans
    98. Shan M, You R, Yuan X, Frazier MV, Porter P, Seryshev A, Hong JS, Song LZ, Zhang Y, Hilsenbeck S, Whitehead L, Zarinkamar N, Perusich S, Corry DB, Kheradmand F. Agonistic induction of PPAR? reverses cigarette smoke-induced emphysema. J Clin Invest. 2014 Mar; 124(3):1371-81. PMID: 24569375; PMCID: PMC3934169.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    99. Parikh N, Hilsenbeck S, Creighton CJ, Dayaram T, Shuck R, Shinbrot E, Xi L, Gibbs RA, Wheeler DA, Donehower LA. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. J Pathol. 2014 Apr; 232(5):522-33. PMID: 24374933; PMCID: PMC4362779.
      Citations: 40     Fields:    Translation:HumansCells
    100. Hatcher RJ, Dong J, Liu S, Bian G, Contreras A, Wang T, Hilsenbeck SG, Li Y, Zhang P. Pttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1008-13. PMID: 24395789; PMCID: PMC3903200.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    101. Fan Y, Ge N, Wang X, Sun W, Mao R, Bu W, Creighton CJ, Zheng P, Vasudevan S, An L, Yang J, Zhao YJ, Zhang H, Li XN, Rao PH, Leung E, Lu YJ, Gray JW, Schiff R, Hilsenbeck SG, Osborne CK, Yang J, Zhang H. Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells. J Pathol. 2014 Jan; 232(1):75-86. PMID: 24122835; PMCID: PMC3966110.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    102. Haricharan S, Dong J, Hein S, Reddy JP, Du Z, Toneff M, Holloway K, Hilsenbeck SG, Huang S, Atkinson R, Woodward W, Jindal S, Borges VF, Gutierrez C, Zhang H, Schedin PJ, Osborne CK, Tweardy DJ, Li Y. Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy. Elife. 2013 Dec 31; 2:e00996. PMID: 24381245; PMCID: PMC3874103.
      Citations: 29     Fields:    Translation:Animals
    103. Ding Y, He D, Florentin D, Frolov A, Hilsenbeck S, Ittmann M, Kadmon D, Miles B, Rowley D, Ayala G. Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6101-11. PMID: 24097862; PMCID: PMC3898797.
      Citations: 22     Fields:    Translation:HumansCells
    104. Robinson JO, Slashinski MJ, Wang T, Hilsenbeck SG, McGuire AL. Participants' recall and understanding of genomic research and large-scale data sharing. J Empir Res Hum Res Ethics. 2013 Oct; 8(4):42-52. PMID: 24169421; PMCID: PMC3995160.
      Citations: 20     Fields:    Translation:Humans
    105. Covington KR, Brusco L, Barone I, Tsimelzon A, Selever J, Corona-Rodriguez A, Brown P, Kumar R, Hilsenbeck SG, Fuqua SA. Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. Breast Cancer Res Treat. 2013 Oct; 141(3):375-384. PMID: 24077732; PMCID: PMC3969415.
      Citations: 21     Fields:    
    106. Ortiz-Perez T, Trevino EJ, Sepulveda KA, Hilsenbeck SG, Wang T, Sedgwick EL. Does formal instruction about the BI-RADS ultrasound lexicon result in improved appropriate use of the lexicon? AJR Am J Roentgenol. 2013 Aug; 201(2):456-61. PMID: 23883229; PMCID: PMC9335931.
      Citations: 2     Fields:    Translation:Humans
    107. Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, Mao S, Pavlick AC, Froehlich AM, Wu MF, Tsimelzon A, Hilsenbeck SG, Chen ES, Zuloaga P, Shaw CA, Rimawi MF, Perou CM, Mills GB, Chang JC, Lewis MT. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013 Aug 01; 73(15):4885-97. PMID: 23737486; PMCID: PMC3732575.
      Citations: 223     Fields:    Translation:HumansAnimalsCells
    108. George SK, Tovar-Sepulveda V, Shen SS, Jian W, Zhang Y, Hilsenbeck SG, Lerner SP, Smith CL. Chemoprevention of BBN-Induced Bladder Carcinogenesis by the Selective Estrogen Receptor Modulator Tamoxifen. Transl Oncol. 2013 Jun; 6(3):244-55. PMID: 23730403; PMCID: PMC3660792.
      Citations: 15     
    109. Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB, Brown PH. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 2013 Jun 01; 73(11):3470-80. PMID: 23633491; PMCID: PMC3853111.
      Citations: 198     Fields:    Translation:HumansAnimalsCells
    110. Wolfswinkel EM, Lopez SN, Weathers WM, Qashqai S, Wang T, Hilsenbeck SG, Rimawi MF, Heller L. Predictors of post-mastectomy reconstruction in an underserved population. J Plast Reconstr Aesthet Surg. 2013 Jun; 66(6):763-9. PMID: 23582504.
      Citations: 5     Fields:    Translation:Humans
    111. Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013 May 10; 31(14):1726-31. PMID: 23569315; PMCID: PMC3641695.
      Citations: 94     Fields:    Translation:HumansCellsCTClinical Trials
    112. York B, Tsimelzon A, Louet JF, Chopra AR, Reineke EL, Zhou S, Stevens RD, Wenner BR, Ilkayeva O, Bain JR, Xu J, Hilsenbeck SG, Newgard CB, O'Malley BW, Sagen JV. Research resource: tissue- and pathway-specific metabolomic profiles of the steroid receptor coactivator (SRC) family. Mol Endocrinol. 2013 Feb; 27(2):366-80. PMID: 23315938; PMCID: PMC3683811.
      Citations: 16     Fields:    Translation:Animals
    113. Pond AC, Bin X, Batts T, Roarty K, Hilsenbeck S, Rosen JM. Fibroblast growth factor receptor signaling is essential for normal mammary gland development and stem cell function. Stem Cells. 2013 Jan; 31(1):178-89. PMID: 23097355; PMCID: PMC3690809.
      Citations: 49     Fields:    Translation:AnimalsCells
    114. Atkinson RL, Yang WT, Rosen DG, Landis MD, Wong H, Lewis MT, Creighton CJ, Sexton KR, Hilsenbeck SG, Sahin AA, Brewster AM, Woodward WA, Chang JC. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Res. 2013; 15(5):R77. PMID: 24008095; PMCID: PMC4053576.
      Citations: 38     Fields:    Translation:HumansCells
    115. Malorni L, Shetty PB, De Angelis C, Hilsenbeck S, Rimawi MF, Elledge R, Osborne CK, De Placido S, Arpino G. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat. 2012 Dec; 136(3):795-804. PMID: 23124476; PMCID: PMC3513514.
      Citations: 74     Fields:    Translation:Humans
    116. Smith CL, Migliaccio I, Chaubal V, Wu MF, Pace MC, Hartmaier R, Jiang S, Edwards DP, Hilsenbeck SG, Oesterreich S, Guti?rrez MC. Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence. Breast Cancer Res Treat. 2012 Nov; 136(1):253-65. PMID: 23015261; PMCID: PMC3511772.
      Citations: 10     Fields:    Translation:HumansCells
    117. Dave B, Landis MD, Tweardy DJ, Chang JC, Dobrolecki LE, Wu MF, Zhang X, Westbrook TF, Hilsenbeck SG, Liu D, Lewis MT. Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One. 2012; 7(8):e30207. PMID: 22879872; PMCID: PMC3412855.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    118. Cerne JZ, Zong L, Jelinek J, Hilsenbeck SG, Wang T, Oesterreich S, McGuire SE. BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients. Breast Cancer Res Treat. 2012 Aug; 135(1):135-43. PMID: 22706629.
      Citations: 2     Fields:    Translation:HumansCells
    119. Xu J, Shetty PB, Feng W, Chenault C, Bast RC, Issa JP, Hilsenbeck SG, Yu Y. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer. 2012 Jun 13; 12:243. PMID: 22695491; PMCID: PMC3476972.
      Citations: 29     Fields:    Translation:HumansCells
    120. York B, Reineke EL, Nikolai BC, Zhou S, Louet JF, Chopra AR, Chen X, Reed G, Noebels J, Adesina AM, Yu H, Wong LJ, Tsimelzon A, Hilsenbeck S, Stevens RD, Wenner BR, Ilkayeva O, Xu J, Newgard CB, O'Malley BW, Sagen JV. Ablation of steroid receptor coactivator-3 resembles the human CACT metabolic myopathy. Cell Metab. 2012 May 02; 15(5):752-63. PMID: 22560224; PMCID: PMC3349072.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    121. Shan M, Yuan X, Song LZ, Roberts L, Zarinkamar N, Seryshev A, Zhang Y, Hilsenbeck S, Chang SH, Dong C, Corry DB, Kheradmand F. Cigarette smoke induction of osteopontin (SPP1) mediates T(H)17 inflammation in human and experimental emphysema. Sci Transl Med. 2012 Jan 18; 4(117):117ra9. PMID: 22261033; PMCID: PMC3956594.
      Citations: 85     Fields:    Translation:HumansAnimalsCells
    122. Rimawi M, Hilsenbeck SG. Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias? J Clin Oncol. 2012 Feb 01; 30(4):453-8. PMID: 22215751.
      Citations: 9     Fields:    Translation:Humans
    123. Oliver JM, Slashinski MJ, Wang T, Kelly PA, Hilsenbeck SG, McGuire AL. Balancing the risks and benefits of genomic data sharing: genome research participants' perspectives. Public Health Genomics. 2012; 15(2):106-14. PMID: 22213783; PMCID: PMC3318928.
      Citations: 52     Fields:    Translation:Humans
    124. Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, Rao M, Yu P, Dominguez-Vidana R, Liang AC, Solimini NL, Bernardi RJ, Yu B, Hsu T, Golding I, Luo J, Osborne CK, Creighton CJ, Hilsenbeck SG, Schiff R, Shaw CA, Elledge SJ, Westbrook TF. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012 Jan 20; 335(6066):348-53. PMID: 22157079; PMCID: PMC4059214.
      Citations: 223     Fields:    Translation:HumansAnimalsCells
    125. Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 2011; 13(6):R121. PMID: 22123186; PMCID: PMC3326563.
      Citations: 119     Fields:    Translation:HumansAnimalsCells
    126. Fisher WE, Hodges SE, Wu MF, Hilsenbeck SG, Brunicardi FC. Assessment of the learning curve for pancreaticoduodenectomy. Am J Surg. 2012 Jun; 203(6):684-90. PMID: 22079032.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    127. McGuire AL, Oliver JM, Slashinski MJ, Graves JL, Wang T, Kelly PA, Fisher W, Lau CC, Goss J, Okcu M, Treadwell-Deering D, Goldman AM, Noebels JL, Hilsenbeck SG. To share or not to share: a randomized trial of consent for data sharing in genome research. Genet Med. 2011 Nov; 13(11):948-55. PMID: 21785360; PMCID: PMC3203320.
      Citations: 48     Fields:    Translation:Humans
    128. Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R. ?1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 2011 Aug 31; 13(4):R84. PMID: 21884573; PMCID: PMC3236347.
      Citations: 86     Fields:    Translation:HumansCells
    129. Dearth RK, Kuiatse I, Wang YF, Liao L, Hilsenbeck SG, Brown PH, Xu J, Lee AV. A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis. BMC Cancer. 2011 Aug 25; 11:377. PMID: 21867536; PMCID: PMC3189189.
      Citations: 5     Fields:    Translation:AnimalsCells
    130. Massarweh S, Tham YL, Huang J, Sexton K, Weiss H, Tsimelzon A, Beyer A, Rimawi M, Cai WY, Hilsenbeck S, Fuqua S, Elledge R. A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011 Oct; 129(3):819-27. PMID: 21792626; PMCID: PMC4477822.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    131. Daves MH, Hilsenbeck SG, Lau CC, Man TK. Meta-analysis of multiple microarray datasets reveals a common gene signature of metastasis in solid tumors. BMC Med Genomics. 2011 Jul 07; 4:56. PMID: 21736749; PMCID: PMC3212952.
      Citations: 29     Fields:    Translation:Humans
    132. Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, Knezevic J, Greene SB, Darr D, Troester MA, Hilsenbeck SG, Medina D, Perou CM, Rosen JM. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2778-83. PMID: 21633010; PMCID: PMC3286979.
      Citations: 123     Fields:    Translation:HumansAnimalsCells
    133. Casa AJ, Potter AS, Malik S, Lazard Z, Kuiatse I, Kim HT, Tsimelzon A, Creighton CJ, Hilsenbeck SG, Brown PH, Oesterreich S, Lee AV. Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat. 2012 Feb; 132(1):61-73. PMID: 21541704; PMCID: PMC3936881.
      Citations: 23     Fields:    Translation:HumansCells
    134. Bu W, Chen J, Morrison GD, Huang S, Creighton CJ, Huang J, Chamness GC, Hilsenbeck SG, Roop DR, Leavitt AD, Li Y. Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer. Oncogene. 2011 Oct 27; 30(43):4399-409. PMID: 21532625; PMCID: PMC3156856.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    135. Dhar SU, Cooper HP, Wang T, Parks B, Staggs SA, Hilsenbeck S, Plon SE. Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Res Treat. 2011 Aug; 129(1):221-7. PMID: 21465171; PMCID: PMC3155891.
      Citations: 15     Fields:    Translation:Humans
    136. Pathiraja TN, Shetty PB, Jelinek J, He R, Hartmaier R, Margossian AL, Hilsenbeck SG, Issa JP, Oesterreich S. Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res. 2011 Jun 15; 17(12):4177-86. PMID: 21459801; PMCID: PMC3955277.
      Citations: 17     Fields:    Translation:HumansCells
    137. Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Fuqua SA, And? S. Loss of Rho GDIa and resistance to tamoxifen via effects on estrogen receptor a. J Natl Cancer Inst. 2011 Apr 06; 103(7):538-52. PMID: 21447808; PMCID: PMC3071355.
      Citations: 31     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    138. Niravath P, Hayes T, Hilsenbeck S. Utility of screening for hepatocellular carcinoma among cirrhotics. Frontline Gastroenterol. 2011 Jul; 2(3):182-187. PMID: 28839606; PMCID: PMC5517217.
      Citations: 1     
    139. Spears M, Oesterreich S, Migliaccio I, Guiterrez C, Hilsenbeck S, Quintayo MA, Pedraza J, Munro AF, Thomas JS, Kerr GR, Jack WJ, Kunkler IH, Cameron DA, Chetty U, Bartlett JM. The p160 ER co-regulators predict outcome in ER negative breast cancer. Breast Cancer Res Treat. 2012 Jan; 131(2):463-72. PMID: 21390497.
      Citations: 4     Fields:    Translation:Humans
    140. Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, Nguyen DX, Pavlova NN, Botero M, Huang J, Bernardi RJ, Schmitt E, Hu G, Li MZ, Dephoure N, Gygi SP, Rao M, Creighton CJ, Hilsenbeck SG, Shaw CA, Muzny D, Gibbs RA, Wheeler DA, Osborne CK, Schiff R, Bentires-Alj M, Elledge SJ, Westbrook TF. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011 Mar 04; 144(5):703-18. PMID: 21376233; PMCID: PMC6014607.
      Citations: 139     Fields:    Translation:HumansCells
    141. Plon SE, Cooper HP, Parks B, Dhar SU, Kelly PA, Weinberg AD, Staggs S, Wang T, Hilsenbeck S. Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med. 2011 Feb; 13(2):148-54. PMID: 21224735; PMCID: PMC3096073.
      Citations: 42     Fields:    Translation:Humans
    142. Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, Wang T, Carboni JM, Gottardis MM, Huang F, Chang JC, Lewis MT, Rimawi MF, Lee AV. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 2011 Apr 15; 17(8):2314-27. PMID: 21177763; PMCID: PMC3073089.
      Citations: 65     Fields:    Translation:HumansAnimalsCells
    143. Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, Ward R, Soliz R, Osborne CK, Schiff R. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res. 2011 Mar 15; 17(6):1351-61. PMID: 21138857; PMCID: PMC3060302.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    144. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol. 2011 Jan 10; 29(2):166-73. PMID: 21135276; PMCID: PMC3058274.
      Citations: 123     Fields:    Translation:HumansCells
    145. Atkinson RL, Zhang M, Diagaradjane P, Peddibhotla S, Contreras A, Hilsenbeck SG, Woodward WA, Krishnan S, Chang JC, Rosen JM. Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med. 2010 Oct 27; 2(55):55ra79. PMID: 20980696; PMCID: PMC4123313.
      Citations: 65     Fields:    Translation:HumansAnimalsCells
    146. Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S, Goode S. Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 2010 Nov 01; 70(21):8517-25. PMID: 20947521; PMCID: PMC2970655.
      Citations: 121     Fields:    Translation:HumansAnimalsCells
    147. McHenry PR, Sears JC, Herrick MP, Chang P, Heckman-Stoddard BM, Rybarczyk M, Chodosh LA, Gunther EJ, Hilsenbeck SG, Rosen JM, Vargo-Gogola T. P190B RhoGAP has pro-tumorigenic functions during MMTV-Neu mammary tumorigenesis and metastasis. Breast Cancer Res. 2010; 12(5):R73. PMID: 20860838; PMCID: PMC3096962.
      Citations: 21     Fields:    Translation:AnimalsCells
    148. Moskovic DJ, Hodges SE, Wu MF, Brunicardi FC, Hilsenbeck SG, Fisher WE. Drain data to predict clinically relevant pancreatic fistula. HPB (Oxford). 2010 Sep; 12(7):472-81. PMID: 20815856; PMCID: PMC3030756.
      Citations: 13     Fields:    Translation:HumansCells
    149. Toneff MJ, Du Z, Dong J, Huang J, Sinai P, Forman J, Hilsenbeck S, Schiff R, Huang S, Li Y. Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis. Neoplasia. 2010 Sep; 12(9):718-26. PMID: 20824048; PMCID: PMC2933692.
      Citations: 18     Fields:    Translation:AnimalsCells
    150. Rodriguez AA, Makris A, Wu MF, Rimawi M, Froehlich A, Dave B, Hilsenbeck SG, Chamness GC, Lewis MT, Dobrolecki LE, Jain D, Sahoo S, Osborne CK, Chang JC. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat. 2010 Aug; 123(1):189-96. PMID: 20582464.
      Citations: 30     Fields:    Translation:HumansCells
    151. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010; 12(3):R40. PMID: 20569503; PMCID: PMC2917035.
      Citations: 117     Fields:    Translation:HumansCells
    152. Pond AC, Herschkowitz JI, Schwertfeger KL, Welm B, Zhang Y, York B, Cardiff RD, Hilsenbeck S, Perou CM, Creighton CJ, Lloyd RE, Rosen JM. Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res. 2010 Jun 15; 70(12):4868-79. PMID: 20501844; PMCID: PMC3005245.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    153. Sweeney AD, Fisher WE, Wu MF, Hilsenbeck SG, Brunicardi FC. Value of pancreatic resection for cancer metastatic to the pancreas. J Surg Res. 2010 May 15; 160(2):268-76. PMID: 20422750.
      Citations: 16     Fields:    Translation:Humans
    154. Massaad CA, Hilsenbeck SG, Serrano F, Pautler RG, P?rez-Torres CJ. In vitro and in vivo magnetic resonance imaging (MRI) detection of GFP through magnetization transfer contrast (MTC). Neuroimage. 2010 Apr 01; 50(2):375-82. PMID: 20060482; PMCID: PMC2824127.
      Citations: 5     Fields:    Translation:Animals
    155. Migliaccio I, Wu MF, Gutierrez C, Malorni L, Mohsin SK, Allred DC, Hilsenbeck SG, Osborne CK, Weiss H, Lee AV. Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Res Treat. 2010 Oct; 123(3):651-60. PMID: 19924529; PMCID: PMC2891842.
      Citations: 13     Fields:    Translation:HumansCells
    156. Chen L, Mayer JA, Krisko TI, Speers CW, Wang T, Hilsenbeck SG, Brown PH. Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res. 2009 Dec 01; 69(23):8853-61. PMID: 19920204; PMCID: PMC2830975.
      Citations: 56     Fields:    Translation:HumansCells
    157. Chang CC, Zhou X, Taylor JJ, Huang WT, Ren X, Monzon F, Feng Y, Rao PH, Lu XY, Fabio F, Hilsenbeck S, Creighton CJ, Jaffe ES, Lau CC. Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma. J Hematol Oncol. 2009 Nov 12; 2:47. PMID: 19909553; PMCID: PMC2789747.
      Citations: 21     Fields:    Translation:HumansCells
    158. Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, Quackenbush J, Hilsenbeck S, Chang J, Brown P. Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res. 2009 Oct 15; 15(20):6327-40. PMID: 19808870; PMCID: PMC2763053.
      Citations: 59     Fields:    Translation:HumansCells
    159. Heckman-Stoddard BM, Vargo-Gogola T, McHenry PR, Jiang V, Herrick MP, Hilsenbeck SG, Settleman J, Rosen JM. Haploinsufficiency for p190B RhoGAP inhibits MMTV-Neu tumor progression. Breast Cancer Res. 2009; 11(4):R61. PMID: 19703301; PMCID: PMC2750123.
      Citations: 20     Fields:    Translation:AnimalsCells
    160. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009 Aug 18; 106(33):13820-5. PMID: 19666588; PMCID: PMC2720409.
      Citations: 707     Fields:    Translation:HumansCells
    161. Chang JC, Hilsenbeck SG, Fuqua SA. Pharmacogenetics of breast cancer: toward the individualization of therapy. Cancer Invest. 2009 Aug; 27(7):699-703. PMID: 19637041.
      Citations: 1     Fields:    Translation:Humans
    162. De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A, Lewis MT, Chamness GC, Hilsenbeck SG, Fuqua SA, And? S. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May; 121(1):1-11. PMID: 19533338; PMCID: PMC2995248.
      Citations: 86     Fields:    Translation:HumansAnimalsCells
    163. Wu MF, Hilsenbeck SG, Tham YL, Kramer R, Elledge RM, Chang JC, Friedman LC. The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer. Breast Cancer Res Treat. 2009 Nov; 118(2):369-75. PMID: 19495957.
      Citations: 8     Fields:    Translation:Humans
    164. Sweeney AD, Wu MF, Hilsenbeck SG, Brunicardi FC, Fisher WE. Value of pancreatic resection for cancer metastatic to the pancreas. J Surg Res. 2009 Oct; 156(2):189-98. PMID: 19375718.
      Citations: 21     Fields:    Translation:Humans
    165. Moran A, Tsimelzon AI, Mastrangelo MA, Wu Y, Yu B, Hilsenbeck SG, Poli V, Tweardy DJ. Prevention of trauma/hemorrhagic shock-induced lung apoptosis by IL-6-mediated activation of Stat3. Clin Transl Sci. 2009 Feb; 2(1):41-9. PMID: 20443866; PMCID: PMC5350783.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    166. Medina D, Kittrell F, Hill J, Zhang Y, Hilsenbeck SG, Bissonette R, Brown PH. Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib. Cancer Prev Res (Phila). 2009 Feb; 2(2):168-74. PMID: 19174577; PMCID: PMC2995265.
      Citations: 7     Fields:    Translation:Animals
    167. Strecker TE, Shen Q, Zhang Y, Hill JL, Li Y, Wang C, Kim HT, Gilmer TM, Sexton KR, Hilsenbeck SG, Osborne CK, Brown PH. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst. 2009 Jan 21; 101(2):107-13. PMID: 19141783; PMCID: PMC2639315.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    168. Hammerich-Hille S, Bardout VJ, Hilsenbeck SG, Osborne CK, Oesterreich S. Low SAFB levels are associated with worse outcome in breast cancer patients. Breast Cancer Res Treat. 2010 Jun; 121(2):503-9. PMID: 19137425.
      Citations: 17     Fields:    Translation:Humans
    169. El-Serag HB, Nurgalieva ZZ, Mistretta TA, Finegold MJ, Souza R, Hilsenbeck S, Shaw C, Darlington G. Gene expression in Barrett's esophagus: laser capture versus whole tissue. Scand J Gastroenterol. 2009; 44(7):787-95. PMID: 19391063; PMCID: PMC2822542.
      Citations: 23     Fields:    Translation:Humans
    170. Ochsner SA, Steffen DL, Hilsenbeck SG, Chen ES, Watkins C, McKenna NJ. GEMS (Gene Expression MetaSignatures), a Web resource for querying meta-analysis of expression microarray datasets: 17beta-estradiol in MCF-7 cells. Cancer Res. 2009 Jan 01; 69(1):23-6. PMID: 19117983; PMCID: PMC2782370.
      Citations: 39     Fields:    Translation:HumansCells
    171. McGuire AL, Diaz CM, Wang T, Hilsenbeck SG. Social networkers' attitudes toward direct-to-consumer personal genome testing. Am J Bioeth. 2009; 9(6-7):3-10. PMID: 19998099; PMCID: PMC2792120.
      Citations: 93     Fields:    Translation:Humans
    172. Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 2008 Sep 15; 68(18):7493-501. PMID: 18794137; PMCID: PMC2556890.
      Citations: 75     Fields:    Translation:HumansAnimalsCells
    173. Siwko SK, Dong J, Lewis MT, Liu H, Hilsenbeck SG, Li Y. Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells--implications for pregnancy-induced protection against breast cancer. Stem Cells. 2008 Dec; 26(12):3205-9. PMID: 18787212; PMCID: PMC2647777.
      Citations: 29     Fields:    Translation:AnimalsCells
    174. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AV. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol. 2008 Sep 01; 26(25):4078-85. PMID: 18757322; PMCID: PMC2654368.
      Citations: 134     Fields:    Translation:HumansCells
    175. Zhang X, Harrington N, Moraes RC, Wu MF, Hilsenbeck SG, Lewis MT. Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo). Breast Cancer Res Treat. 2009 Jun; 115(3):505-21. PMID: 18563554; PMCID: PMC5300001.
      Citations: 55     Fields:    Translation:HumansCells
    176. Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, Medina D, Tsimelzon A, Hilsenbeck S, Green JE, Michalowska AM, Rosen JM. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 2008 Jun 15; 68(12):4674-82. PMID: 18559513; PMCID: PMC2459340.
      Citations: 158     Fields:    Translation:AnimalsCells
    177. Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg. 2008 May; 247(5):732-8. PMID: 18438108.
      Citations: 53     Fields:    Translation:Humans
    178. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008 May 07; 100(9):672-9. PMID: 18445819.
      Citations: 817     Fields:    Translation:Humans
    179. Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009 Mar; 114(2):287-99. PMID: 18425577; PMCID: PMC2635926.
      Citations: 41     Fields:    Translation:HumansCells
    180. Shen Q, Uray IP, Li Y, Zhang Y, Hill J, Xu XC, Young MR, Gunther EJ, Hilsenbeck SG, Colburn NH, Chodosh LA, Brown PH. Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors. Cancer Prev Res (Phila). 2008 Jun; 1(1):45-55. PMID: 19138935; PMCID: PMC2577387.
      Citations: 13     Fields:    Translation:AnimalsCells
    181. Shah D, Fisher WE, Hodges SE, Wu MF, Hilsenbeck SG, Charles Brunicardi F. Preoperative prediction of complete resection in pancreatic cancer. J Surg Res. 2008 Jun 15; 147(2):216-20. PMID: 18498873.
      Citations: 10     Fields:    Translation:Humans
    182. Fisher WE, Chai C, Hodges SE, Wu MF, Hilsenbeck SG, Brunicardi FC. Effect of BioGlue on the incidence of pancreatic fistula following pancreas resection. J Gastrointest Surg. 2008 May; 12(5):882-90. PMID: 18273671.
      Citations: 15     Fields:    Translation:Humans
    183. Alten JA, Moran A, Tsimelzon AI, Mastrangelo MA, Hilsenbeck SG, Poli V, Tweardy DJ. Prevention of hypovolemic circulatory collapse by IL-6 activated Stat3. PLoS One. 2008 Feb 13; 3(2):e1605. PMID: 18270592; PMCID: PMC2225503.
      Citations: 14     Fields:    Translation:AnimalsCells
    184. Rae JM, Skaar TC, Hilsenbeck SG, Oesterreich S. The role of single nucleotide polymorphisms in breast cancer metastasis. Breast Cancer Res. 2008; 10(1):301. PMID: 18226176; PMCID: PMC2374952.
      Citations: 5     Fields:    Translation:HumansAnimals
    185. Fisher WE, Hodges SE, Yagnik V, Wu MF, Hilsenbeck SG, Raijman IL, Brunicardi FC, Mor?n FE. Accuracy of CT in predicting malignant potential of cystic pancreatic neoplasms. HPB (Oxford). 2008; 10(6):483-90. PMID: 19088937; PMCID: PMC2597321.
      Citations: 23     Fields:    
    186. Li Y, Zhang Y, Hill J, Shen Q, Kim HT, Xu X, Hilsenbeck SG, Bissonnette RP, Lamph WW, Brown PH. The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res. 2007 Oct 15; 13(20):6224-31. PMID: 17947490.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    187. Yee RW, Sperling HG, Kattek A, Paukert MT, Dawson K, Garcia M, Hilsenbeck S. Isolation of the ocular surface to treat dysfunctional tear syndrome associated with computer use. Ocul Surf. 2007 Oct; 5(4):308-15. PMID: 17938840.
      Citations: 1     Fields:    Translation:Humans
    188. Redell MS, Tsimelzon A, Hilsenbeck SG, Tweardy DJ. Conditional overexpression of Stat3alpha in differentiating myeloid cells results in neutrophil expansion and induces a distinct, antiapoptotic and pro-oncogenic gene expression pattern. J Leukoc Biol. 2007 Oct; 82(4):975-85. PMID: 17634277.
      Citations: 9     Fields:    Translation:AnimalsCells
    189. Herynk MH, Parra I, Cui Y, Beyer A, Wu MF, Hilsenbeck SG, Fuqua SA. Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res. 2007 Jun 01; 13(11):3235-43. PMID: 17545528; PMCID: PMC4484622.
      Citations: 27     Fields:    Translation:Humans
    190. Chang JC, Makris A, Gutierrez MC, Hilsenbeck SG, Hackett JR, Jeong J, Liu ML, Baker J, Clark-Langone K, Baehner FL, Sexton K, Mohsin S, Gray T, Alvarez L, Chamness GC, Osborne CK, Shak S. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat. 2008 Mar; 108(2):233-40. PMID: 17468949.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    191. Moraes RC, Zhang X, Harrington N, Fung JY, Wu MF, Hilsenbeck SG, Allred DC, Lewis MT. Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development. 2007 Mar; 134(6):1231-42. PMID: 17287253.
      Citations: 103     Fields:    Translation:HumansAnimalsCells
    192. Kim HT, Kong G, Denardo D, Li Y, Uray I, Pal S, Mohsin S, Hilsenbeck SG, Bissonnette R, Lamph WW, Johnson K, Brown PH. Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 2006 Dec 15; 66(24):12009-18. PMID: 17178900.
      Citations: 23     Fields:    Translation:HumansAnimals
    193. Huang S, Podsypanina K, Chen Y, Cai W, Tsimelzon A, Hilsenbeck S, Li Y. Wnt-1 is dominant over neu in specifying mammary tumor expression profiles. Technol Cancer Res Treat. 2006 Dec; 5(6):565-71. PMID: 17121432.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    194. Ma XJ, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA, Osborne CK, Allred DC, Erlander MG. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006 Oct 01; 24(28):4611-9. PMID: 17008703.
      Citations: 74     Fields:    Translation:Humans
    195. Nguyen DM, Sam K, Tsimelzon A, Li X, Wong H, Mohsin S, Clark GM, Hilsenbeck SG, Elledge RM, Allred DC, O'Connell P, Chang JC. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res. 2006 Sep 01; 12(17):5047-54. PMID: 16951220.
      Citations: 31     Fields:    Translation:Humans
    196. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006 Aug 15; 107(4):696-704. PMID: 16826579.
      Citations: 99     Fields:    Translation:Humans
    197. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006 Aug 15; 66(16):8266-73. PMID: 16912207.
      Citations: 65     Fields:    Translation:HumansAnimalsCells
    198. Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, Horii A, Zhang ZY, Nicholson RI, Fuqua SA. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res. 2006 Jun 01; 66(11):5950-9. PMID: 16740736; PMCID: PMC4484848.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    199. Shen Q, Zhang Y, Uray IP, Hill JL, Kim HT, Lu C, Young MR, Gunther EJ, Hilsenbeck SG, Chodosh LA, Colburn NH, Brown PH. The AP-1 transcription factor regulates postnatal mammary gland development. Dev Biol. 2006 Jul 15; 295(2):589-603. PMID: 16678816.
      Citations: 21     Fields:    Translation:Animals
    200. Bourgogne A, Hilsenbeck SG, Dunny GM, Murray BE. Comparison of OG1RF and an isogenic fsrB deletion mutant by transcriptional analysis: the Fsr system of Enterococcus faecalis is more than the activator of gelatinase and serine protease. J Bacteriol. 2006 Apr; 188(8):2875-84. PMID: 16585749; PMCID: PMC1446981.
      Citations: 64     Fields:    Translation:Cells
    201. Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brown M, Dowsett M, Hilsenbeck SG, Kumar R, Johnston SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C. Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):997s-1000s. PMID: 16467115.
      Citations: 2     Fields:    Translation:Humans
    202. Kim HJ, Cui X, Hilsenbeck SG, Lee AV. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1013s-1018s. PMID: 16467118.
      Citations: 29     Fields:    Translation:HumansCells
    203. Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T, Hilsenbeck S, Wong H, Osborne CK, O'Connell P, Chang JC. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat. 2006 Feb; 95(3):229-33. PMID: 16322899.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    204. Hilsenbeck SG, Osborne CK. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1049s-1055s. PMID: 16467123.
      Citations: 2     Fields:    Translation:Humans
    205. Lee S, Mohsin SK, Mao S, Hilsenbeck SG, Medina D, Allred DC. Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer. Breast Cancer Res. 2006; 8(1):R6. PMID: 16417654; PMCID: PMC1413990.
      Citations: 41     Fields:    Translation:Humans
    206. Tham YL, Gomez LF, Mohsin S, Gutierrez MC, Weiss H, Hilsenbeck SG, Elledge RM, Chamness GC, Osborne CK, Allred DC, Chang JC. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 2005 Dec; 94(3):279-84. PMID: 16261403.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    207. Behbod F, Xian W, Shaw CA, Hilsenbeck SG, Tsimelzon A, Rosen JM. Transcriptional profiling of mammary gland side population cells. Stem Cells. 2006 Apr; 24(4):1065-74. PMID: 16282442.
      Citations: 17     Fields:    Translation:AnimalsCells
    208. Martin MD, Hilsenbeck SG, Mohsin SK, Hopp TA, Clark GM, Osborne CK, Allred DC, O'Connell P. Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat. 2006 Jan; 95(1):7-12. PMID: 16244788.
      Citations: 19     Fields:    Translation:Humans
    209. Osborne CK, Schiff R, Arpino G, Lee AS, Hilsenbeck VG. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast. 2005 Dec; 14(6):458-65. PMID: 16236516.
      Citations: 36     Fields:    Translation:Humans
    210. Lu C, Shen Q, Kim H, Hilsenbeck S, Brown PH, DuPr? E. cFos is critical for MCF-7 breast cancer cell growth. Oncogene. 2005 Sep 29; 24(43):6516-24. PMID: 16027729.
      Citations: 28     Fields:    Translation:HumansCells
    211. Jeong JW, Lee KY, Kwak I, White LD, Hilsenbeck SG, Lydon JP, DeMayo FJ. Identification of murine uterine genes regulated in a ligand-dependent manner by the progesterone receptor. Endocrinology. 2005 Aug; 146(8):3490-505. PMID: 15845616.
      Citations: 75     Fields:    Translation:Animals
    212. Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol. 2005 Jul 20; 23(21):4687-94. PMID: 15837971.
      Citations: 13     Fields:    Translation:Humans
    213. Kong G, Kim HT, Wu K, DeNardo D, Hilsenbeck SG, Xu XC, Lamph WW, Bissonnette R, Dannenberg AJ, Brown PH. The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res. 2005 Apr 15; 65(8):3462-9. PMID: 15833882.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    214. Chang JC, Hilsenbeck SG, Fuqua SA. The promise of microarrays in the management and treatment of breast cancer. Breast Cancer Res. 2005; 7(3):100-4. PMID: 15987438; PMCID: PMC1143565.
      Citations: 12     Fields:    Translation:Humans
    215. Chen DT, Rosenstein DL, Muthappan P, Hilsenbeck SG, Miller FG, Emanuel EJ, Wendler D. Research with stored biological samples: what do research participants want? Arch Intern Med. 2005 Mar 28; 165(6):652-5. PMID: 15795341.
      Citations: 44     Fields:    Translation:Humans
    216. Chang JC, Hilsenbeck SG, Fuqua SA. Genomic approaches in the management and treatment of breast cancer. Br J Cancer. 2005 Feb 28; 92(4):618-24. PMID: 15714204; PMCID: PMC2361866.
      Citations: 10     Fields:    Translation:HumansCells
    217. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H, O'Connell P. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol. 2005 Feb 20; 23(6):1169-77. PMID: 15718313.
      Citations: 59     Fields:    Translation:Humans
    218. Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005 Apr 10; 23(11):2460-8. PMID: 15710948.
      Citations: 96     Fields:    Translation:HumansCTClinical Trials
    219. Jatoi I, Tsimelzon A, Weiss H, Clark GM, Hilsenbeck SG. Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat. 2005 Jan; 89(2):173-8. PMID: 15692760.
      Citations: 22     Fields:    Translation:Humans
    220. Kalidas M, Hilsenbeck S, Brown P. Defining the role of raloxifene for the prevention of breast cancer. J Natl Cancer Inst. 2004 Dec 01; 96(23):1731-3. PMID: 15572750.
      Citations: 1     Fields:    Translation:Humans
    221. DeNardo DG, Kim HT, Hilsenbeck S, Cuba V, Tsimelzon A, Brown PH. Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Mol Endocrinol. 2005 Feb; 19(2):362-78. PMID: 15514030.
      Citations: 37     Fields:    Translation:HumansCells
    222. Lin SC, Lee KF, Nikitin AY, Hilsenbeck SG, Cardiff RD, Li A, Kang KW, Frank SA, Lee WH, Lee EY. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res. 2004 May 15; 64(10):3525-32. PMID: 15150107.
      Citations: 55     Fields:    Translation:AnimalsCells
    223. Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, Fuqua SA. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004 Apr 15; 10(8):2751-60. PMID: 15102680.
      Citations: 84     Fields:    Translation:HumansAnimalsCells
    224. Han ES, Wu Y, McCarter R, Nelson JF, Richardson A, Hilsenbeck SG. Reproducibility, sources of variability, pooling, and sample size: important considerations for the design of high-density oligonucleotide array experiments. J Gerontol A Biol Sci Med Sci. 2004 Apr; 59(4):306-15. PMID: 15071073.
      Citations: 19     Fields:    Translation:Animals
    225. Drysdale M, Bourgogne A, Hilsenbeck SG, Koehler TM. atxA controls Bacillus anthracis capsule synthesis via acpA and a newly discovered regulator, acpB. J Bacteriol. 2004 Jan; 186(2):307-15. PMID: 14702298; PMCID: PMC305762.
      Citations: 50     Fields:    Translation:Cells
    226. Fuqua SA, Chang JC, Hilsenbeck SG. Genomic approaches to understanding and treating breast cancer. Breast Dis. 2004; 19:35-46. PMID: 15687696.
      Citations: 3     Fields:    
    227. Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003 Dec 17; 95(24):1825-33. PMID: 14679152.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    228. Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Gutierrez MC, Lucci A, Kalidas M, Granchi T, Scott BG, Allred DC, Chang JC. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer. 2003 Dec; 4(5):348-53. PMID: 14715110.
      Citations: 23     Fields:    Translation:Humans
    229. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell P. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003 Aug 02; 362(9381):362-9. PMID: 12907009.
      Citations: 196     Fields:    Translation:Humans
    230. Bourgogne A, Drysdale M, Hilsenbeck SG, Peterson SN, Koehler TM. Global effects of virulence gene regulators in a Bacillus anthracis strain with both virulence plasmids. Infect Immun. 2003 May; 71(5):2736-43. PMID: 12704148; PMCID: PMC153248.
      Citations: 72     Fields:    Translation:Cells
    231. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):353-61. PMID: 12618500.
      Citations: 271     Fields:    Translation:HumansCells
    232. Liu Q, Hilsenbeck S, Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood. 2003 May 15; 101(10):4078-87. PMID: 12531793.
      Citations: 53     Fields:    Translation:HumansCells
    233. Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonette R, Brown PH. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. 2002 Nov 15; 62(22):6376-80. PMID: 12438218.
      Citations: 55     Fields:    Translation:AnimalsCells
    234. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002 Oct 31; 21(50):7680-9. PMID: 12400010.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    235. Berry DA, Iversen ES, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002 Jun 01; 20(11):2701-12. PMID: 12039933.
      Citations: 153     Fields:    Translation:Humans
    236. Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, Brown PH. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev. 2002 May; 11(5):467-74. PMID: 12010861.
      Citations: 46     Fields:    Translation:Animals
    237. Sivaraman L, Gay J, Hilsenbeck SG, Shine HD, Conneely OM, Medina D, O'Malley BW. Effect of selective ablation of proliferating mammary epithelial cells on MNU induced rat mammary tumorigenesis. Breast Cancer Res Treat. 2002 May; 73(1):75-83. PMID: 12083633.
      Citations: 7     Fields:    Translation:AnimalsCells
    238. Medina D, Sivaraman L, Hilsenbeck SG, Conneely O, Ginger M, Rosen J, Omalle BW. Mechanisms of hormonal prevention of breast cancer. Ann N Y Acad Sci. 2001 Dec; 952:23-35. PMID: 11795441.
      Citations: 21     Fields:    Translation:HumansAnimals
    239. Chang J, Hilsenbeck SG, Sng JH, Wong J, Ragu GC. Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res. 2001 Jun; 7(6):1739-42. PMID: 11410514.
      Citations: 15     Fields:    Translation:Humans
    240. Ludes-Meyers JH, Liu Y, Hilsenbeck SG, Brown PH, Mu?oz-Medellin D. AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene. 2001 May 17; 20(22):2771-80. PMID: 11420689.
      Citations: 22     Fields:    Translation:HumansCells
    241. Hansen RK, Parra I, Hilsenbeck SG, Himelstein B, Fuqua SA. Hsp27-induced MMP-9 expression is influenced by the Src tyrosine protein kinase yes. Biochem Biophys Res Commun. 2001 Mar 23; 282(1):186-93. PMID: 11263990.
      Citations: 12     Fields:    Translation:HumansCells
    242. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34. PMID: 11106684.
      Citations: 64     Fields:    Translation:HumansAnimalsCells
    243. Hammond LA, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S. Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model. Eur J Cancer. 2000 Dec; 36(18):2430-6. PMID: 11094320.
      Citations: 3     Fields:    Translation:HumansAnimals
    244. Przepiorka D, Blamble D, Hilsenbeck S, Danielson M, Krance R, Chan KW. Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant. 2000 Sep; 26(6):601-5. PMID: 11041564.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    245. Wu K, Kim HT, Rodriquez JL, Munoz-Medellin D, Mohsin SK, Hilsenbeck SG, Lamph WW, Gottardis MM, Shirley MA, Kuhn JG, Green JE, Brown PH. 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin Cancer Res. 2000 Sep; 6(9):3696-704. PMID: 10999763.
      Citations: 30     Fields:    Translation:Animals
    246. Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, Allred DC. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 2000 Aug 01; 60(15):4026-9. PMID: 10945602.
      Citations: 76     Fields:    Translation:Humans
    247. Weitman S, Barrera H, Moore R, Gonzalez C, Marty J, Hilsenbeck S, MacDonald JR, Waters SJ, Von Hoff D. MGI 114: augmentation of antitumor activity when combined with topotecan. J Pediatr Hematol Oncol. 2000 Jul-Aug; 22(4):306-14. PMID: 10959900.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    248. Han E, Hilsenbeck SG, Richardson A, Nelson JF. cDNA expression arrays reveal incomplete reversal of age-related changes in gene expression by calorie restriction. Mech Ageing Dev. 2000 Jun 20; 115(3):157-74. PMID: 10906510.
      Citations: 10     Fields:    Translation:Animals
    249. Zellars RC, Hilsenbeck SG, Clark GM, Allred DC, Herman TS, Chamness GC, Elledge RM. Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol. 2000 May; 18(9):1906-13. PMID: 10784631.
      Citations: 10     Fields:    Translation:Humans
    250. Leach CT, Koo FC, Kuhls TL, Hilsenbeck SG, Jenson HB. Prevalence of Cryptosporidium parvum infection in children along the Texas-Mexico border and associated risk factors. Am J Trop Med Hyg. 2000 May; 62(5):656-61. PMID: 11289680.
      Citations: 14     Fields:    Translation:HumansAnimals
    251. Fernandes NF, Schwesinger WH, Hilsenbeck SG, Gross GW, Bay MK, Sirinek KR, Schenker S. Laparoscopic cholecystectomy and cirrhosis: a case-control study of outcomes. Liver Transpl. 2000 May; 6(3):340-4. PMID: 10827236.
      Citations: 16     Fields:    Translation:Humans
    252. Hilsenbeck SG. RESPONSE: re: measure once or twice-does It really matter? J Natl Cancer Inst. 1999 Oct 20; 91(20):1780A-1781. PMID: 10528033.
      Citations:    Fields:    
    253. Cody JD, Ghidoni PD, DuPont BR, Hale DE, Hilsenbeck SG, Stratton RF, Hoffman DS, Muller S, Schaub RL, Leach RJ, Kaye CI. Congenital anomalies and anthropometry of 42 individuals with deletions of chromosome 18q. Am J Med Genet. 1999 Aug 27; 85(5):455-62. PMID: 10405442.
      Citations: 42     Fields:    Translation:HumansCells
    254. O'Connell P, Fischbach K, Hilsenbeck S, Mohsin SK, Fuqua SA, Clark GM, Osborne CK, Allred DC. Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst. 1999 Aug 18; 91(16):1391-7. PMID: 10451444.
      Citations: 4     Fields:    Translation:HumansCells
    255. Leach CT, Koo FC, Hilsenbeck SG, Jenson HB. The epidemiology of viral hepatitis in children in South Texas: increased prevalence of hepatitis A along the Texas-Mexico border. J Infect Dis. 1999 Aug; 180(2):509-13. PMID: 10395871.
      Citations: 6     Fields:    Translation:Humans
    256. Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999 Aug; 17(8):2334-40. PMID: 10561295.
      Citations: 100     Fields:    Translation:Humans
    257. Hansen RK, Parra I, Lemieux P, Oesterreich S, Hilsenbeck SG, Fuqua SA. Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat. 1999 Jul; 56(2):187-96. PMID: 10573111.
      Citations: 50     Fields:    Translation:HumansCells
    258. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999 May; 13(5):787-96. PMID: 10319328.
      Citations: 105     Fields:    Translation:HumansAnimalsCells
    259. Hilsenbeck SG, Von Hoff DD. Measure once or twice -- does it really matter? J Natl Cancer Inst. 1999 Mar 17; 91(6):494-5. PMID: 10088614.
      Citations: 1     Fields:    Translation:Humans
    260. Hilsenbeck SG, Friedrichs WE, Schiff R, O'Connell P, Hansen RK, Osborne CK, Fuqua SA. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst. 1999 Mar 03; 91(5):453-9. PMID: 10070945.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    261. Britten CD, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res. 1999 Mar 01; 59(5):1049-53. PMID: 10070962.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    262. Diab SG, Hilsenbeck SG, Izbicka E, Weitman SD, Von Hoff DD. Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system. Anticancer Drugs. 1999 Mar; 10(3):303-7. PMID: 10327037.
      Citations: 2     Fields:    Translation:HumansCells
    263. Britten CD, Izbicka E, Hilsenbeck S, Lawrence R, Davidson K, Cerna C, Gomez L, Rowinsky EK, Weitman S, Von Hoff DD. Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemother Pharmacol. 1999; 44(2):105-10. PMID: 10412943.
      Citations: 8     Fields:    Translation:Humans
    264. Weitman S, Mangold G, Marty J, Dexter D, Hilsenbeck S, Rake J, Juniewicz P, Von Hoff D. Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Cancer Chemother Pharmacol. 1999; 43(5):402-8. PMID: 10100596.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    265. Gazitt Y, Rothenberg ML, Hilsenbeck SG, Fey V, Thomas C, Montegomrey W. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int J Oncol. 1998 Oct; 13(4):839-48. PMID: 9735415.
      Citations: 13     Fields:    Translation:HumansCells
    266. Allred DC, Hilsenbeck SG. Biomarkers in benign breast disease: risk factors for breast cancer. J Natl Cancer Inst. 1998 Sep 02; 90(17):1247-8. PMID: 9731725.
      Citations: 5     Fields:    Translation:Humans
    267. Revankar SG, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Redding SW, Rinaldi MG, Hilsenbeck SG, Patterson TF. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. Am J Med. 1998 Jul; 105(1):7-11. PMID: 9688014.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    268. Diab SG, Hilsenbeck SG, de Moor C, Clark GM, Osborne CK, Ravdin PM, Elledge RM. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998 May; 16(5):1655-60. PMID: 9586875.
      Citations: 12     Fields:    Translation:Humans
    269. Osborne CK, Elledge RM, Brown PH, Hilsenbeck SG. BRCA1 in clinical breast cancer. Breast Dis. 1998 Apr; 10(1-2):77-88. PMID: 15687551.
      Citations:    Fields:    
    270. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG, Rose DW. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):2920-5. PMID: 9501191; PMCID: PMC19670.
      Citations: 142     Fields:    Translation:HumansAnimalsCells
    271. Hopp RM, Ransom N, Hilsenbeck SG, Papermaster DS, Windle JJ. Apoptosis in the murine rd1 retinal degeneration is predominantly p53-independent. Mol Vis. 1998 Mar 02; 4:5. PMID: 9485488.
      Citations: 5     Fields:    Translation:AnimalsCells
    272. Rodriguez GI, Kuhn JG, Weiss GR, Hilsenbeck SG, Eckardt JR, Thurman A, Rinaldi DA, Hodges S, Von Hoff DD, Rowinsky EK. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood. 1998 Mar 01; 91(5):1533-41. PMID: 9473217.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    273. Lee AV, Hilsenbeck SG, Yee D. IGF system components as prognostic markers in breast cancer. Breast Cancer Res Treat. 1998 Feb; 47(3):295-302. PMID: 9516083.
      Citations: 17     Fields:    Translation:Humans
    274. Jenson HB, Grant GM, Ench Y, Heard P, Thomas CA, Hilsenbeck SG, Moyer MP. Immunofluorescence microscopy and flow cytometry characterization of chemical induction of latent Epstein-Barr virus. Clin Diagn Lab Immunol. 1998 Jan; 5(1):91-7. PMID: 9455888; PMCID: PMC121399.
      Citations: 5     Fields:    Translation:HumansCells
    275. Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998; 52(1-3):227-37. PMID: 10066085.
      Citations: 61     Fields:    Translation:HumansCells
    276. Rodriguez GI, Kuhn JG, Weiss G, De La Cruz P, New P, Fields SM, Eckardt JR, Campbell L, Clark GM, Hilsenbeck SG, Von Hoff DD. A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion. Invest New Drugs. 1998; 16(1):57-67. PMID: 9740545.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    277. Clark GM, Allred DC, Hilsenbeck SG, Chamness GC, Osborne CK, Jones D, Lee WH. Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res. 1997 Dec 15; 57(24):5505-8. PMID: 9407959.
      Citations: 15     Fields:    Translation:HumansAnimals
    278. Sharma S, Raymond E, Soda H, Sun D, Hilsenbeck SG, Sharma A, Izbicka E, Windle B, Von Hoff DD. Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Ann Oncol. 1997 Nov; 8(11):1063-74. PMID: 9426325.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    279. Gazitt Y, Hilsenbeck S. Pitfalls in the RNA-based PCR amplification of the CDRIII sequence for quantitation of minimal residual disease in multiple myeloma (Commentary). Oncol Rep. 1997 Nov-Dec; 4(6):1387-90. PMID: 21590258.
      Citations:    Fields:    
    280. Ravdin PM, de Moor CA, Hilsenbeck SG, Samoszuk MK, Vendely PM, Clark GM. Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients. Cancer Lett. 1997 Jun 24; 116(2):177-83. PMID: 9215861.
      Citations: 3     Fields:    Translation:Humans
    281. De Nino LA, Lawrence VA, Averyt EC, Hilsenbeck SG, Dhanda R, Page CP. Preoperative spirometry and laparotomy: blowing away dollars. Chest. 1997 Jun; 111(6):1536-41. PMID: 9187170.
      Citations: 5     Fields:    Translation:Humans
    282. Van den Berg CL, Cox GN, Stroh CA, Hilsenbeck SG, Weng CN, McDermott MJ, Pratt D, Osborne CK, Coronado-Heinsohn EB, Yee D. Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer. 1997 Jun; 33(7):1108-13. PMID: 9376191.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    283. Diab SG, Yu YY, Hilsenbeck SG, Allred DC, Elledge RM. WAF1/CIP1 protein expression in human breast tumors. Breast Cancer Res Treat. 1997 Apr; 43(2):99-103. PMID: 9131264.
      Citations: 9     Fields:    Translation:HumansCells
    284. Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK, Gr?ndahl-Hansen J, Br?nner N. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat. 1997 Apr; 43(2):153-63. PMID: 9131271.
      Citations: 13     Fields:    Translation:HumansCells
    285. Hundley JE, Koester SK, Troyer DA, Hilsenbeck SG, Barrington RE, Windle JJ. Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors. Cancer Res. 1997 Feb 15; 57(4):600-3. PMID: 9044833.
      Citations: 12     Fields:    Translation:AnimalsCells
    286. Hundley JE, Koester SK, Troyer DA, Hilsenbeck SG, Subler MA, Windle JJ. Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol Cell Biol. 1997 Feb; 17(2):723-31. PMID: 9001226; PMCID: PMC231798.
      Citations: 27     Fields:    Translation:AnimalsCells
    287. Sharma JJ, Razvillas B, Stephens CD, Hilsenbeck SG, Sharma A, Rothenberg ML. Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. Invest New Drugs. 1997; 15(4):361-4. PMID: 9547680.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    288. Lemieux P, Oesterreich S, Lawrence JA, Steeg PS, Hilsenbeck SG, Harvey JM, Fuqua SA. The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis. 1997; 17(3):113-23. PMID: 9702938.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    289. Rocha RL, Hilsenbeck SG, Jackson JG, VanDenBerg CL, Weng Cn, Lee AV, Yee D. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res. 1997 Jan; 3(1):103-9. PMID: 9815544.
      Citations: 66     Fields:    Translation:Humans
    290. Zhang QX, Hilsenbeck SG, Fuqua SA, Borg A. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol. 1996 Nov; 59(3-4):251-60. PMID: 9010317.
      Citations: 19     Fields:    Translation:HumansCells
    291. Lawrence VA, Dhanda R, Hilsenbeck SG, Page CP. Risk of pulmonary complications after elective abdominal surgery. Chest. 1996 Sep; 110(3):744-50. PMID: 8797421.
      Citations: 31     Fields:    Translation:Humans
    292. Oesterreich S, Hilsenbeck SG, Ciocca DR, Allred DC, Clark GM, Chamness GC, Osborne CK, Fuqua SA. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996 Jul; 2(7):1199-206. PMID: 9816288.
      Citations: 9     Fields:    Translation:Humans
    293. Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst. 1996 May 01; 88(9):601-6. PMID: 8609661.
      Citations: 31     Fields:    Translation:HumansCells
    294. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol. 1996 Apr; 14(4):1128-35. PMID: 8648367.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    295. Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res. 1996 Mar; 2(3):585-92. PMID: 9816207.
      Citations: 24     Fields:    Translation:HumansCells
    296. Hilsenbeck SG, Clark GM. Practical p-value adjustment for optimally selected cutpoints. Stat Med. 1996 Jan 15; 15(1):103-12. PMID: 8614741.
      Citations: 16     Fields:    Translation:Humans
    297. De Boever AL, Keeling SD, Hilsenbeck S, Van Sickels JE, Bays RA, Rugh JD. Signs of temporomandibular disorders in patients with horizontal mandibular deficiency. J Orofac Pain. 1996; 10(1):21-7. PMID: 8995913.
      Citations:    Fields:    Translation:Humans
    298. Lawrence VA, Hilsenbeck SG, Mulrow CD, Dhanda R, Sapp J, Page CP. Incidence and hospital stay for cardiac and pulmonary complications after abdominal surgery. J Gen Intern Med. 1995 Dec; 10(12):671-8. PMID: 8770719.
      Citations: 62     Fields:    Translation:Humans
    299. Sevin BU, Nadji M, Lampe B, Lu Y, Hilsenbeck S, Koechli OR, Averette HE. Prognostic factors of early stage cervical cancer treated by radical hysterectomy. Cancer. 1995 Nov 15; 76(10 Suppl):1978-86. PMID: 8634988.
      Citations: 19     Fields:    Translation:Humans
    300. Elledge RM, Lock-Lim S, Allred DC, Hilsenbeck SG, Cordner L. p53 mutation and tamoxifen resistance in breast cancer. Clin Cancer Res. 1995 Oct; 1(10):1203-8. PMID: 9815913.
      Citations: 9     Fields:    Translation:HumansCells
    301. Isola JJ, Kallioniemi OP, Chu LW, Fuqua SA, Hilsenbeck SG, Osborne CK, Waldman FM. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol. 1995 Oct; 147(4):905-11. PMID: 7573366; PMCID: PMC1871005.
      Citations: 56     Fields:    Translation:Humans
    302. Martinez AJ, Mills MB, Jaceldo KB, Tio FO, Aigbivbalu IB, Hilsenbeck SB, Yee RW. Standardization of conjunctival impression cytology. Cornea. 1995 Sep; 14(5):515-22. PMID: 8536466.
      Citations: 3     Fields:    Translation:AnimalsCells
    303. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995 May 17; 87(10):746-50. PMID: 7563152.
      Citations: 67     Fields:    Translation:HumansAnimals
    304. Murphy LC, Hilsenbeck SG, Dotzlaw H, Fuqua SA. Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. Clin Cancer Res. 1995 Feb; 1(2):155-9. PMID: 9815968.
      Citations: 4     Fields:    Translation:HumansCells
    305. Takahashi S, Goldring S, Katz M, Hilsenbeck S, Williams R, Roodman GD. Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest. 1995 Jan; 95(1):167-71. PMID: 7814611; PMCID: PMC295397.
      Citations: 18     Fields:    Translation:HumansCells
    306. Yee D, Sharma J, Hilsenbeck SG. Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. J Natl Cancer Inst. 1994 Dec 07; 86(23):1785-9. PMID: 7525978.
      Citations: 8     Fields:    Translation:Humans
    307. Reddy KB, Yee D, Hilsenbeck SG, Coffey RJ, Osborne CK. Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression. Cell Growth Differ. 1994 Dec; 5(12):1275-82. PMID: 7696176.
      Citations: 12     Fields:    Translation:HumansCells
    308. Hilsenbeck SG, Chamness GC, Elledge RM, Pujol P. Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer. 1994 Sep 01; 74(5):1601-6. PMID: 8062191.
      Citations: 6     Fields:    Translation:Humans
    309. Shimada Y, Rothenberg M, Hilsenbeck SG, Burris HA, Degen D, Von Hoff DD. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs. 1994 Apr; 5(2):202-6. PMID: 8049503.
      Citations: 9     Fields:    Translation:HumansCells
    310. Ravdin PM, Tandon AK, Allred DC, Clark GM, Fuqua SA, Hilsenbeck SH, Chamness GC, Osborne CK. Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol. 1994 Mar; 12(3):467-74. PMID: 8120545.
      Citations: 7     Fields:    Translation:Humans
    311. McGuire SE, Hilsenbeck SG, Figueroa JA, Jackson JG, Yee D. Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. Cancer Lett. 1994 Feb 28; 77(1):25-32. PMID: 7512885.
      Citations: 12     Fields:    Translation:Humans
    312. Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol. 1994; 34(2):89-95. PMID: 8194171.
      Citations: 16     Fields:    Translation:AnimalsCells
    313. Clark GM, Hilsenbeck SG, Ravdin PM, De Laurentiis M, Osborne CK. Prognostic factors: rationale and methods of analysis and integration. Breast Cancer Res Treat. 1994; 32(1):105-12. PMID: 7819579.
      Citations: 7     Fields:    Translation:Humans
    314. Schneider BG, Hilsenbeck SG, Hensel CH, Pekkel V, Shelton CH, Pulitzer DR, Allred DC, Rodr?guez-Mart?nez HA, Guti?rrez-D?az ME. p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos. Virchows Arch. 1994; 424(2):187-93. PMID: 8180781.
      Citations: 7     Fields:    Translation:HumansCells
    315. Fuqua SA, Oesterreich S, Hilsenbeck SG, Von Hoff DD, Eckardt J, Osborne CK. Heat shock proteins and drug resistance. Breast Cancer Res Treat. 1994; 32(1):67-71. PMID: 7819588.
      Citations: 19     Fields:    Translation:Humans
    316. Rothenberg ML, Kuhn JG, Burris HA, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 1993 Nov; 11(11):2194-204. PMID: 8229134.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    317. Figueroa JA, Sharma J, Jackson JG, McDermott MJ, Hilsenbeck SG, Yee D. Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. J Cell Physiol. 1993 Nov; 157(2):229-36. PMID: 7693722.
      Citations: 17     Fields:    Translation:HumansCells
    318. Kroenke K, Lawrence VA, Theroux JF, Tuley MR, Hilsenbeck S. Postoperative complications after thoracic and major abdominal surgery in patients with and without obstructive lung disease. Chest. 1993 Nov; 104(5):1445-51. PMID: 8222804.
      Citations: 38     Fields:    Translation:Humans
    319. Oesterreich S, Weng CN, Qiu M, Hilsenbeck SG, Osborne CK, Fuqua SA. The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res. 1993 Oct 01; 53(19):4443-8. PMID: 8402609.
      Citations: 74     Fields:    Translation:HumansCells
    320. Hilsenbeck SG, Raub WA, Sridhar KS. Prognostic factors in lung cancer based on multivariate analysis. Am J Clin Oncol. 1993 Aug; 16(4):301-9. PMID: 8328408.
      Citations: 2     Fields:    Translation:Humans
    321. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 1993 Jul 15; 53(14):3369-73. PMID: 8324747.
      Citations: 74     Fields:    Translation:HumansCells
    322. Choy H, Rodriguez FF, Koester S, Hilsenbeck S, Von Hoff DD. Investigation of taxol as a potential radiation sensitizer. Cancer. 1993 Jun 01; 71(11):3774-8. PMID: 8098270.
      Citations: 34     Fields:    Translation:HumansCells
    323. Hilsenbeck SG, Clark GM. Surrogate endpoints in chemoprevention of breast cancer: guidelines for evaluation of new biomarkers. J Cell Biochem Suppl. 1993; 17G:205-11. PMID: 8007700.
      Citations:    Fields:    Translation:Humans
    324. Ross M, Degen D, Hilsenbeck SG, Von Hoff DD, Hanauske AR. In vitro activity of the benzotriazine dioxide SR 4233 against human tumour colony-forming units. Eur J Cancer. 1993; 29A(3):423-5. PMID: 8398345.
      Citations: 2     Fields:    Translation:Humans
    325. Hilsenbeck SG, Depenbrock H, Danhauser-Riedl S, Block T, Nekarda H, Fellbaum C, Aapro MS, Bissery MC, Rastetter J, Vogel M, et al. Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents. Eur J Cancer. 1993; 29A(14):2009-14. PMID: 7904173.
      Citations: 10     Fields:    Translation:HumansCells
    326. Burris HA, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG, Von Hoff DD. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst. 1992 Dec 02; 84(23):1816-20. PMID: 1331485.
      Citations: 40     Fields:    Translation:HumansCells
    327. Hilsenbeck SG, Kurucz C, Duncan RC. Estimation of completeness and adjustment of age-specific and age-standardized incidence rates. Biometrics. 1992 Dec; 48(4):1249-62. PMID: 1290800.
      Citations: 5     Fields:    Translation:Humans
    328. Sevin BU, Nadji M, Averette HE, Hilsenbeck S, Smith D, Lampe B. Microinvasive carcinoma of the cervix. Cancer. 1992 Oct 15; 70(8):2121-8. PMID: 1394041.
      Citations: 9     Fields:    Translation:Humans
    329. Holzmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst. 1992 Oct 07; 84(19):1486-91. PMID: 1359152.
      Citations: 35     Fields:    Translation:Humans
    330. Sridhar KS, Raub WA, Duncan RC, Hilsenbeck S. The increasing recognition of adenosquamous lung carcinoma (1977-1986). Am J Clin Oncol. 1992 Aug; 15(4):356-62. PMID: 1514535.
      Citations: 2     Fields:    Translation:Humans
    331. Vogel CL, Azevedo S, Hilsenbeck S, East DR, Ayub J. Survival after first recurrence of breast cancer. The Miami experience. Cancer. 1992 Jul 01; 70(1):129-35. PMID: 1606535.
      Citations: 14     Fields:    Translation:Humans
    332. Hilsenbeck SG, Allred DC. Improved methods of estimating mitotic activity in solid tumors. Hum Pathol. 1992 Jun; 23(6):601-2. PMID: 1592380.
      Citations: 4     Fields:    Translation:Humans
    333. Wolfson AH, Sightler SE, Markoe AM, Schwade JG, Averette HE, Ganjei P, Hilsenbeck SG. The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol. 1992 May; 45(2):142-6. PMID: 1592280.
      Citations: 17     Fields:    Translation:Humans
    334. Degen D, Hilsenbeck SG, Bissery MC, Von Hoff DD, Hanauske AR. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs. 1992 Apr; 3(2):121-4. PMID: 1356030.
      Citations: 17     Fields:    Translation:HumansCells
    335. Degen D, Marshall MH, Hilsenbeck SG, Banks P, Stuckey J, Leahy M, Von Hoff DD, Hanauske AR. Effects of recombinant human interleukin-1 alpha on clonogenic growth of primary human tumors in vitro. J Immunother (1991). 1992 Apr; 11(3):155-8. PMID: 1515420.
      Citations:    Fields:    Translation:HumansCells
    336. Degen D, Marshall MH, Hilsenbeck SG, Grindey GB, Von Hoff DD, Hanauske AR. Activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units. Anticancer Drugs. 1992 Apr; 3(2):143-6. PMID: 1525392.
      Citations: 9     Fields:    Translation:HumansCells
    337. McGuire WL, Hilsenbeck S, Clark GM. Optimal mastectomy timing. J Natl Cancer Inst. 1992 Mar 04; 84(5):346-8. PMID: 1738187.
      Citations: 6     Fields:    Translation:Humans
    338. Degen D, Marshall MH, Hilsenbeck SG, McPhillips JJ, Von Hoff DD, Hanauske AR. Preclinical activity of ilmofosine against human tumor colony forming units in vitro. Anticancer Drugs. 1992 Feb; 3(1):43-6. PMID: 1623215.
      Citations: 5     Fields:    Translation:Humans
    339. Ravdin PM, Clark GM, Hilsenbeck SG, Owens MA, Vendely P, Pandian MR, McGuire WL. A demonstration that breast cancer recurrence can be predicted by neural network analysis. Breast Cancer Res Treat. 1992; 21(1):47-53. PMID: 1391974.
      Citations: 11     Fields:    Translation:Humans
    340. Hilsenbeck SG, Clark GM, McGuire WL. Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat. 1992; 22(3):197-206. PMID: 1391986.
      Citations: 34     Fields:    Translation:Humans
    341. Sridhar KS, Hussein AM, Hilsenbeck S, Cairns V. Five-drug antiemetic combination for cisplatin chemotherapy. Cancer Invest. 1992; 10(3):191-9. PMID: 1581829.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    342. Knorr KL, Hilsenbeck SG, Wenger CR, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GM. Making the most of your prognostic factors: presenting a more accurate survival model for breast cancer patients. Breast Cancer Res Treat. 1992; 22(3):251-62. PMID: 1391991.
      Citations: 2     Fields:    Translation:Humans
    343. Sridhar KS, Raub W, Duncan RC, Hilsenbeck S, Richman SP. Lung carcinoma in 1,336 patients. Am J Clin Oncol. 1991 Dec; 14(6):496-508. PMID: 1957838.
      Citations: 3     Fields:    Translation:Humans
    344. Sevin BU, Ramos R, Gerhardt RT, Guerra L, Hilsenbeck S, Averette HE. Comparative efficacy of short-term versus long-term cefoxitin prophylaxis against postoperative infection after radical hysterectomy: a prospective study. Obstet Gynecol. 1991 May; 77(5):729-34. PMID: 2014087.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    345. Petru E, Sevin BU, Averette HE, Koechli OR, Hilsenbeck S. Long-term survival in stage III and IV ovarian cancer. Arch Gynecol Obstet. 1991; 249(2):87-93. PMID: 1953056.
      Citations: 1     Fields:    Translation:Humans
    346. Boike GM, Petru E, Sevin BU, Averette HE, Chou TC, Penalver M, Donato D, Schiano M, Hilsenbeck SG, Perras J. Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line. Gynecol Oncol. 1990 Sep; 38(3):315-22. PMID: 2121626.
      Citations: 3     Fields:    Translation:HumansCells
    347. Petru E, Sevin BU, Averette HE, Koechli OR, Perras JP, Hilsenbeck S. Comparison of three tumor markers--CA-125, lipid-associated sialic acid (LSA), and NB/70K--in monitoring ovarian cancer. Gynecol Oncol. 1990 Aug; 38(2):181-6. PMID: 2387533.
      Citations: 4     Fields:    Translation:Humans
    348. Moffat FL, Ketcham AS, Robinson DS, Legaspi A, Ghandur-Mnaymneh L, Hilsenbeck S. Segmental mastectomy without radiotherapy for T1 and small T2 breast carcinomas. Arch Surg. 1990 Mar; 125(3):364-9. PMID: 2306183.
      Citations: 4     Fields:    Translation:Humans
    349. Hilsenbeck SG. Quality control practices in centralized tumor registries in North America. J Clin Epidemiol. 1990; 43(11):1201-12. PMID: 2243256.
      Citations: 1     Fields:    Translation:Humans
    350. Barnavon Y, Iwaki H, Bash JA, Brettschneider F, Hilsenbeck S, Darnell E, Wallack MK. Treatment of murine hepatic metastases with vaccinia colon oncolysates and IL-2. J Surg Res. 1988 Dec; 45(6):523-30. PMID: 3263545.
      Citations: 3     Fields:    Translation:AnimalsCells
    351. Hilsenbeck SG. Early termination of a phase II clinical trial. Control Clin Trials. 1988 Sep; 9(3):177-88. PMID: 3180826.
      Citations:    Fields:    Translation:Humans
    352. Davila E, Vogel CL, East D, Cairns V, Hilsenbeck S. Clinical trial of high-dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature. Cancer. 1988 Jun 01; 61(11):2161-7. PMID: 2966667.
      Citations: 1     Fields:    Translation:Humans
    353. Suster S, Hilsenbeck S, Rywlin AM. Reactive histiocytic hyperplasia with hemophagocytosis in hematopoietic organs: a reevaluation of the benign hemophagocytic proliferations. Hum Pathol. 1988 Jun; 19(6):705-12. PMID: 3378789.
      Citations: 14     Fields:    Translation:HumansCells
    354. Sridhar KS, Varki J, Donnelly E, Davila E, Benedetto P, Hilsenbeck S, Thurer RJ, Rao RK, Fountzilas G, Beattie EJ. Toxicity of FED chemotherapy in non-small-cell lung cancer. Am J Clin Oncol. 1987 Dec; 10(6):499-506. PMID: 2446489.
      Citations: 1     Fields:    Translation:HumansCells
    355. Pitchenik AE, Becker DM, Hilsenbeck SG, Trapido EJ. Cancer among Haitians in Florida. Cancer. 1987 Jan 01; 59(1):184-8. PMID: 3024799.
      Citations: 3     Fields:    Translation:Humans
    356. Wang G, Vogel CL, Hilsenbeck SG, Voigt W, Thomsen S. Value of 8S/4S fractionation of estrogen receptors (ER) for prediction of response to hormonal manipulation in metastatic breast cancer. Breast Cancer Res Treat. 1984; 4(4):283-8. PMID: 6518294.
      Citations: 1     Fields:    Translation:Humans
    HILSENBECK's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (1155)
    Co-Authors (223)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors